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A MECHANISM FOR TRIF ADAPTOR-BIASED SIGNALING BY TOLL-LIKE 
RECEPTOR 4 
 
Joseph Peterson Kolb, Jr. 
November 20, 2014 
 Host cells respond to bacterial lipid A through Toll-like receptor 4 (TLR4).  
Activation of TLR4 by lipid A triggers a response that involves two main adaptor 
proteins, MyD88 and TRIF.  MyD88-dependent gene expression is associated with 
proinflammatory protein production, while TRIF-dependent gene expression is essential 
for optimal activation of adaptive immunity by antigen-presenting cells.  Detoxified, 
monophosphoryl lipid A agonists (MPLA or synthetic MLA) were previously suggested 
to elicit TRIF-biased TLR4 signaling; that is, induction of weaker MyD88-associated 
gene expression but relatively intact TRIF-dependent gene expression when compared to 
fully active diphosphoryl lipid A (lipid A).  In this work, we explored potential 
mechanisms by which monophosphoryl lipid A could induce TRIF-biased signaling in 
mouse cells.  TRIF-dependent and MyD88-associated gene expression induced by both 
MPLA and lipid A was reduced to a similar extent by CD14 ablation, indicating that 
these two agonists do not differentially utilize CD14, despite this coreceptor’s primary 
role in directing the TRIF signaling pathway.  In a second study, we demonstrated that 
the observation of TRIF-biased gene expression by sMLA was not because the agonist 
induced a TRIF-biased gene expression profile, but rather that TLR4 itself was TRIF-
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biased.  The potencies of three different agonists were significantly higher for the 
induction of expression of TRIF-dependent genes than they were for induction of 
expression of MyD88-associated genes.  Autocrine and paracrine signaling by type I 
interferons contributed to higher potency of TLR4 agonists for induction of TRIF-
dependent gene expression because blocking the type I interferon receptor before agonist 
treatment diminished the effect.  We propose that TLR4 is a prime target for vaccine 
adjuvants.  The therapeutic window of TLR4 agonists may be inherently large due to the 
ease with which TRIF-dependent genes required for adaptive priming are activated 
relative to MyD88-dependent genes associated with toxicity
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DISCOVERY OF THE LIPOPOLYSACCHARIDE RECEPTOR 
 For many years, immunologists knew that T and B cell activation in response to a 
protein antigen required the addition of certain mixtures called adjuvants, but the way 
adjuvants worked was largely unknown.  In 1989, the preeminent scientist Charles 
Janeway proposed the existence of evolutionarily ancient pattern recognition receptors 
(PRRs) expressed on innate immune cells that had evolved to respond to conserved 
microbial products called pathogen-associated molecular patterns (PAMPs) (1).  Janeway 
postulated that the cellular response elicited by these PAMPs must somehow provide a 
second signal to lymphocytes, instructing their activation, and allowing them to 
discriminate between self and non-self antigens.  In the following years, intensive 
searches for PRRs and their corresponding PAMPs were carried out. 
 One of the most well studied PAMPs is lipopolysaccharide (LPS).  LPS is a major 
component of the outer membrane of Gram-negative bacteria that promotes structural 
integrity and provides the bacteria a protective barrier to toxic compounds in the 
extracellular environment (2).  The inflammatory and immunostimulatory effects of LPS, 
initially known as endotoxin, had long been recognized since its discovery by Richard 
Pfeiffer in 1892 (3).  For example, endotoxin tolerance, or the hypo-responsiveness of a 
host to LPS treatment following an initial LPS exposure, was first described in 1946 by 
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Beeson (4).  In addition, LPS was known to induce B cell proliferation since the early 
1970s (5, 6). 
 In 1969, Sultzer published work describing a strain of mouse which was highly 
resistant to the toxic effects of LPS (7).  This mouse, called C3H/HeJ, provided evidence 
that responsiveness to LPS was genetically encoded.  It was not until the 1980s that 
strides began to be made in determining the nuts and bolts of the LPS response.  Tobias et 
al. (8) were the first to isolate the acute phase LPS-binding protein (LBP) from rabbit 
serum and to provide evidence of its interaction with LPS.  A few years later, another 
protein, CD14, was shown to bind LBP-LPS complexes (9).  CD14 is expressed on the 
surface of cells of the myelomonocytic lineage (10).  Initially, many considered CD14 to 
be a polyspecific PRR responsible for inducing the inflammatory response to LPS as well 
as Gram-positive bacterial components (11), but several lines of evidence indicated that 
CD14 was not alone in propagating the LPS response.  First, CD14 is expressed on the 
cell membrane via a short glycosylphosphatidylinositol (GPI) anchor which is incapable 
of transducing a signal by itself (12).  Second, deacylated LPS, which is antagonistic to 
LPS in human cells, inhibited the inflammatory response to LPS without preventing LPS 
binding to CD14, indicating that LPS might induce its signal at a different location (13).  
Third, the activity of LPS antagonists was dependent upon the species from which a cell 
was derived but independent of the species from which CD14 was derived (14).  In 
addition, experiments in CD14-deficient macrophages demonstrated the existence of 
CD14-independent LPS activation (15). 
 Several breakthroughs in our understanding of LPS recognition occurred in the 
late 1990s.  In 1996, Lemaitre et al. (16) published work demonstrating that the 
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Drosophila Toll signaling pathway, which was known to control embryonic dorsoventral 
patterning, was also responsible for the induction of an antifungal response by way of 
activation of an NF-κB-related transcription factor.  Most importantly, this work 
implicated the existence of conserved Toll-NF-κB-like signaling pathways responsible 
for non-adaptive activation of antimicrobial genes in mammalian cells (17).  In the 
following year, Janeway and Medzhitov (18) cloned the human homologue of Drosophila 
Toll (hToll) and expressed a constitutively active form of it in the human monocytic cell 
line THP-1.  Cells which expressed this hToll mutant also expressed higher levels of 
proinflammatory cytokines and the T cell costimulatory molecule CD80.  This data 
provided the first evidence that Toll signaling pathway activation in the context of 
infection was potentially involved in the activation of innate immune cells, which were, 
in turn, required to educate adaptive immune cells. 
 In 1998, Janeway’s PAMP and PRR hypothesis was clearly born out with the 
discovery by Beutler and colleagues (19) that LPS hyporesponsive C3H/HeJ and 
C57BL/10ScCr mice bore mutations in the Toll-like receptor 4 (TLR4) gene.  In 
particular, C3H/HeJ mice have a point mutation in the intracellular signaling domain of 
TLR4, and C57BL/10ScCr mice carry a TLR4 null mutation.  This work clearly 
demonstrated that TLR4 was responsible for inducing the inflammatory response to LPS.  
Interestingly, Janeway had unwittingly stumbled upon the LPS receptor before Beutler 
because hToll was actually the human TLR4 gene (20).  Shortly after Beutler’s 
publication, it was discovered that a coreceptor called MD-2, along with TLR4, made up 
the complete LPS receptor complex.  MD-2, in complex with TLR4, directly bound LPS, 
while TLR4 was responsible for transducing the intracellular signal (21, 22).  The 
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discovery of TLR4 ignited a flurry of research activities in the field of innate immune 
recognition of pathogen components that continues today.  It did not take long for much 
of the TLR4 signaling mechanism to be elucidated. 
 
THE TLR4 SIGNALING PATHWAY 
 TLR4 is expressed on a wide variety of immune and non-immune cells including 
monocytes, macrophages, dendritic cells, neutrophils, B cells, and endothelial cells, but 
the majority of TLR4 signaling work has been performed in macrophages and dendritic 
cells.  In order for TLR4 signaling to take place, monomeric LPS must be delivered to the 
receptor.  This process is accomplished by two coreceptors, LBP and CD14 (discussed in 
detail in Chapter III).  LBP in the serum extracts LPS monomers from bacteria or 
aggregates, and catalytically transfers them to CD14 (23, 24).  CD14 is expressed on the 
cell surface and is found in soluble form in the serum (12, 25).  CD14 transfers LPS from 
its binding pockets to MD-2 complexed with TLR4 on the cell surface (26). 
In general, the LPS molecule contains three structural components: the O-
polysaccharide or O-antigen, the core oligosaccharide, and lipid A (reviewed in (27)).  
The O-polysaccharide is the most variable moiety, consisting of 0 to 50 repeating sugar 
subgroups.  This high variability is responsible for the diversity of host antibody 
serotypes to Gram-negative bacteria.  The core oligosaccharide is much less variable than 
the O-polysaccharide.  It consists of an outer core composed of common hexose sugars 
and an inner core consisting of rare sugars such as 3-deoxy-D-manno-octulosonic acid 
(Kdo) and L-glycero-D-manno heptose.  Lipid A is the highly hydrophobic core of LPS 
which anchors into the outer Gram-negative bacteria membrane.  It is generally 
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composed of a di-glucosamine headgroup with two phosphate groups at the 1 and 4’ 
positions.  Up to 4 amide or ester linked primary acyl chains are attached to the 
diglucosamine, and up to 3 additional secondary acyl chains may be linked to the primary 
chains (up to 7 acyl chains in total).  Lipid A is called the “endotoxic principle” because 
it alone is sufficient to induce a response like that of the complete LPS molecule (28).  
This is because lipid A is the component of LPS that binds directly to MD-2 and interacts 
with TLR4 (29). 
TLR4 is a type I transmembrane protein.  Its extracellular N-terminal domain is 
made up of leucine-rich repeats (LRRs) which form a horseshoe-like shape.  TLR4’s C-
terminal cytoplasmic region is homologous to the intracellular domain of the IL-1 
receptor and is, therefore, called the Toll/IL-1 receptor (TIR) domain.  MD-2 is 
composed of two sandwiched anti-parallel β-sheets that form the lipid A-binding pocket 
(30).  The inside of the pocket is lined with hydrophobic residues that accommodate lipid 
A’s fatty acyl chains, and the pocket’s rim contains hydrophilic residues which are also 
important for ligand interaction (29, 30).  MD-2 stably binds with TLR4 on the concave 
surface of its extracellular domain through charge-charge interactions (31). 
Lipid A interaction with MD-2 at the cell surface induces the dimerization of two 
TLR4:MD-2 complexes (also called heterotetramerization) that brings TIR domains in 
the cytoplasmic tails into close proximity with one another (29, 31-33).  It is thought that 
the close interaction of TIR domains promotes the recruitment of signaling adaptor 
proteins.  There are four main adaptor proteins associated with TLR signaling: myeloid 
differentiation primary response gene 88 (MyD88), MyD88 adaptor-like (Mal), TIR 
domain-containing adaptor inducing interferon-β (IFN-β) (TRIF), and TRIF-related 
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adaptor molecule (TRAM).  TLR4 is unique in that is the only TLR which utilizes all 
four adaptor proteins (34).  The MyD88-dependent and the TRIF-dependent signaling 
pathways have unique characteristics and are required for the activation of different sets 
of genes. 
Upon TLR4 activation (Fig. 1), Mal and MyD88 are rapidly recruited to the 
cytoplasmic TIR domain of TLR4 and bind to it through their own TIR domains.  Mal is 
localized to the cell membrane via a phosphatidylinositol 4,5-bisphosphate (PIP2) 
binding domain, and facilitates the recruitment of MyD88 (35).  These events initiate the 
formation of the myddosome, a helical oligomer of IL-1 receptor-associated kinases 
(IRAKs)-4, -1, or -2 which interact through their death domains (36).  Close association 
causes IRAKs to become phosphorylated and to be released from the myddosome to then 
interact with TNF receptor-associated factor 6 (TRAF6), an E3 ubiquitin ligase (37). 
Both IRAK1 and TRAF6 are K63-polyubiquitinated in the process (38-40).  TGF-β-
associated kinase-1 (TAK1)-binding proteins (TABs), the regulatory components of 
TAK1, bind to the long ubiquitin chains attached to TRAF6 through their zinc-finger 
ubiquitin-binding domains (41, 42).  This then leads to activation of TAK-1, which 
activates downstream MAPKs.  Inhibitor of NF-κB kinase-γ (IKKγ) also binds to 
polyubiquitinated TRAF6, which brings the catalytic subunits IKKα and IKKβ into close 
proximity to TAK1 (37, 41, 43).  TAK1 phosphorylates IKKβ, which allows the IKK 
complex to phosphorylate IκB and mark it for ubiquitin-dependent degradation.  This 
process allows NF-κB to enter the nucleus.  Due to its robust NF-κB and MAPK 




Several minutes after MyD88-dependent signaling is initiated, TLR4:MD-2 
complexes are endocytosed via a CD14-dependent pathway (47).  This process induces 
the recruitment TRAM and TRIF to the TLR4 cytoplasmic TIR domains (48-50), which 
activates the E3 ubiquitin ligase TRAF3 (51).  TRAF3 become polyubiquitinated and 
activates TANK-binding kinase-1 (TBK1), which then activates IKKε.  This signaling 
cascade results in the activating phosphorylation of the transcription factor interferon 
regulatory factor 3 (IRF3), which is required for type I interferon production (52-55).  
TRIF signaling also overlaps with the MyD88 pathway by recruiting the E3 ubiquitin 
ligases TRAF6 and Pelino1 which polyubiquitinate receptor interacting protein-1 (RIP1) 
(56, 57).  Ubiquitinated RIP1 recruits and activates TAK1 and the IKK complex, which 
then activate MAPKs and NF-κB (58).  As a result of this overlap in signaling pathways, 
TRIF-deficiency frequently decreases production of proinflammatory mediators 
associated with the MyD88 pathway (59-62). 
 
THE TLR4 AGONIST MONOPHOSPHORYL LIPID A AS A VACCINE ADJUVANT 
Unquestionably, one of the most important medical achievements in current 
human history is vaccination against disease causing pathogens.  Vaccination has saved 
countless lives and countless dollars in medical treatment expenses by eradicating or 
dramatically decreasing the incidence of many diseases worldwide.  Despite the success 
of whole-pathogen vaccines, which make use of inactivated or attenuated microbes, there 
is a still a need for the development of new and safer vaccine strategies.  Current 
vaccination strategies have been unsuccessful in preventing intractable diseases such as 
cancer and HIV, as well as emerging threats such as Ebola (which at the time of writing 
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this dissertation is causing a severe epidemic in West Africa and global concern).  In 
addition, the rare occurrence of serious adverse events associated with whole-pathogen 
vaccination, whether real or perceived, has caused many to opt out of vaccination due to 
safety concerns (63). 
The answers to some of these problems may lie in subunit vaccination.  This 
strategy uses only the essential microbial antigens, and not the whole organism, to 
stimulate immunity.  Although subunit vaccines are considered very safe, protein 
antigens alone are usually inherently weak stimulators of the innate arm of the immune 
system, which is essential to long-term adaptive immunity.  Therefore, adjuvants 
(PAMPs or other immunostimulatory compounds) must be formulated with subunit 
vaccines. 
The first successful clinical vaccine adjuvant was alum (non-crystalline gels of 
aluminum salts), which has been used in vaccines since 1926 (64).  To date, alum is the 
most commonly used adjuvant.  Alum promotes delivery of antigen to APCs and 
stimulates APC maturation by inducing an intracellular signaling pathway caused by its 
interaction with cell membrane lipids (65).  Alum promotes a Th2 humoral immune 
response typified by non-complement fixing antibody isotypes.  While these responses 
are effective against microbes where neutralizing are required for protection, they are not 
well suited for stimulating protective immunity to intracellular pathogens or to 
endogenous antigens present in pre-cancerous, transformed cells (66).  Therefore, there is 
still a need for the development of new vaccine adjuvants which stimulate different facets 
of the immune response. 
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LPS has long been known as an effective vaccine adjuvant, but its strong 
pyrogenicity and association with septic shock has precluded its use in the clinical 
setting.  Beginning in the late 1970s, Edgar Ribi systematically studied the biological 
properties of chemically modified LPS.  Acid hydrolysis of Salmonella minnesota Re595 
(deep rough mutant) LPS, which contains a mixture of congeners with different numbers 
of acyl chains, removed the core-oligosaccharide (Kdo), as well as the diglucosamine 1-
phosphate group (67).  The resulting molecule (Fig. 2), called monophosphoryl lipid A 
(MPLA), was shown to be at least 1,000 times less toxic than parental LPS in a battery of 
tests, including chick embryo lethality and rabbit pyrogenicity (68).  Surprisingly, MPLA 
retained 100% of the ability of LPS to induce tumor regression and systemic immunity in 
the transplantable line-10 tumor model in guinea pigs (68).  This seminal work 
demonstrated that the beneficial immunomodulatory functions of LPS could be separated 
from its toxicity. 
  Ribi’s discovery would make a dramatic impact in the field of vaccine adjuvant 
development with the purchase and mass production of clinical grade MPLA called MPL 
adjuvant by Corixa Corporation and later GlaxoSmithKline (GSK).  MPL adjuvant is 
approved for use in the hepatitis B virus vaccine Fendrix in Europe and in the human 
papillomavirus (HPV) vaccine Cervarix in the USA.  In both of these vaccines, MPL 
adjuvant is used in combination with alum in the GSK adjuvant system called AS04.  The 
benefits of MPL were clearly shown in follow-up studies in women vaccinated with 
either Cervarix or Merck’s Gardasil, which is adjuvanted with alum alone.  Up to 24 
months after vaccination, Cervarix was shown to induce significantly higher titers of 
HPV-18 and HPV-16 neutralizing antibodies, and better antigen specific CD4 T cell and 
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memory B cell responses (69, 70).  To date, MPL adjuvant is the only TLR agonist-based 
adjuvant to be approved by the FDA.  Its success demonstrated the feasibility of using 
TLR4 agonists in the clinical setting and caused a dramatic increase in studies aimed at 
elucidating the structural features of LPS or lipid A required for beneficial adjuvanticity 
but low toxicity, with the hope that these features could be fine tuned. 
 
MONOPHOSPHORYL LIPID A AS A TRIF-BIASED AGONIST OF TLR4 
 The basis of MPLA’s unique adjuvant properties has been debated.  Early studies 
comparing the ability of MPLA and LPS to elicit gene products downstream of TLR4 
seemed to indicate that MPLA was a less potent version of LPS (71-73).  Over a dose 
range of 0.1 to 1000 ng/ml, MPLA was weaker than LPS in the induction of Ifng, 
Il12p40, and Il12p35 mRNA in mouse peritoneal macrophages (71).  MPLA was also 
weaker than LPS in stimulating IL-12 protein production by both mouse macrophages 
and human monocyte-derived DC (71, 72).  In contrast, additional studies indicated that 
MPLA may retain the ability to induce certain responses just as well as LPS, while 
remaining weak in others (71, 74, 75).  More MPLA than LPS was required to induce 
endotoxin tolerance in mice, but at doses where equivalent tolerance was induced, MPLA 
was still less capable than LPS at eliciting proinflammatory cytokines (74).  Also, MPLA 
was reported to induce a similar abundance of Il1b mRNA compared to LPS, but lower 
amounts of IL-1β protein (75).  Still, others concluded that MPLA may be better able to 
induce certain responses than LPS.  For example, MPLA treatment induced more Il10 
mRNA expression in mouse macrophages than LPS (71).  Lower production of 
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proinflammatory cytokines like IL-1β, and higher production of anti-inflammatory 
cytokines like IL-10 were proposed to contribute to the low toxicity of MPLA. 
 During the time in which MPL adjuvant was showing promise in the clinic, our 
lab became interested in determining how a low inflammatory environment elicited by 
MPLA would specifically affect the quality of T cell priming.  Our initial studies (76) 
demonstrated that MPLA was better able than LPS to induce early clonal expansion of 
ovalbumin-specific CD4 T cells, despite being about 5 times less toxic.  In contrast, 
MPLA was less capable than LPS at stimulating long-term retention of antigen-specific 
CD4 T cells. 
 A breakthrough in our understanding of MPLA’s adjuvanticity occurred with the 
work of Mata-Haro et al. (77).  In this study, 30 ug of MPLA and 10 ug of LPS induced 
indistinguishable expansion kinetics and numbers of antigen-specific CD4 and CD8 T 
cells in an adoptive transfer model with OT-I and OT-II T cells in mice.  Strikingly, 
MPLA was not equivalent to LPS in inducing production of certain serum cytokines and 
chemokines during this T cell activation.  Serum levels of MyD88-associated proteins, 
such as IL-6, IL-1β, and IFN-γ were significantly lower when MPLA was used as an 
adjuvant as opposed to LPS.  In contrast, production of TRIF-associated proteins such as 
G-CSF and IP-10 was induced similarly by MPLA and LPS.  This phenomenon, which 
we termed “TRIF-bias,” was confirmed by gene chip mRNA expression analysis on 
spleen cells harvested 6 hours after immunization with MPLA or LPS.  TRIF-bias was 
also shown in vitro with mouse macrophages.  MPLA was significantly weaker than LPS 
in inducing MyD88-associated IL-6 production and NF-κB activation, but was equivalent 
to LPS in TRIF-dependent IP-10 production and IRF3 activation. 
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 In this same study, we demonstrated that the TRIF pathway, and not the MyD88 
pathway, was required for the early expansion of antigen-specific CD4 and CD8 T cells 
with MPLA or LPS as adjuvant.  This observation and the association of MyD88 
signaling with proinflammatory outcomes gave rise to the hypothesis that TRIF-biased 
signaling by MPLA allowed it to be an effective adjuvant without overwhelming toxicity. 
 Our lab went on to demonstrate that the absence of the 1-phosphate on lipid A 
was a potential determinate of TRIF-biased TLR4 signaling in mice (78, 79).  The 
synthetic monophosphoryl lipid A based on the E. coli chemotype, which we call sMLA, 
was equivalent to diphosphoryl lipid A (called sLipid A in this dissertation) (Fig. 3) in the 
induction of TRIF-dependent gene products but weaker in MyD88-associated gene 
products at the concentrations tested (78).  In addition, we showed that sMLA, like 
MPLA, was equivalent to sLipid A in its induction of Il1b mRNA, but weaker in 
induction of IL-1β protein due to its weak activation of the MyD88-dependent NLRP3 
inflammasome (79).  Still, we were aware of the fact that TLR4 signaling caused by 
MPLA and sMLA was not completely devoid of MyD88 activity.  For example, sMLA 
induced more sustained MyD88-dependent SHIP1 phosphatase than sLipid A (80).  In 
addition, sMLA was capable of inducing the same amount of many MyD88-associated 
events as sLipid A if sMLA was given at a higher dose (78, 81).  Therefore, TRIF-biased 
signaling by MPLA and sMLA was always appreciated as being more nuanced than 







 Although we have begun to characterize many of the qualitative aspects of TLR4 
signaling by MPLA and sMLA, we have yet to determine a definitive mechanism for 
TRIF-bias.  Observations of TLR4 adaptor signaling biases have been published by other 
labs, but adaptor bias remains a controversial topic within the scientific community.  The 
goal of this dissertation was to expand our understanding of TRIF-biased signaling by 
monophosphorylated lipid A agonists and to define a potential mechanism for its 
occurrence.  In Chapter III, the role of the coreceptor CD14 in signaling by MPLA is 
analyzed to determine whether this receptor, which plays a prominent role in TRIF 
signaling, is utilized differently by a TRIF-biased agonist.  In Chapter IV, we refine our 
definition of TRIF-biased signaling and propose a mechanism which depends upon the 
interaction of TLR4 and the type I interferon receptor signaling pathways.  These 
findings have direct implications for the design and utilization of TLR4 agonists as 
vaccine adjuvants.  They may also provide insight into the coevolution of the microbiome 





Fig. 1.  The TLR4 signaling pathway.  LPS or lipid A induced heterotetramerization of 
TLR4:MD-2 causes signaling through the MyD88- and TRIF-dependent pathways.  
MyD88 signaling occurs first from the cell membrane and leads to rapid activation of 
MAPKs and NF-κB.  MAPKs activate transcription factors, such as the AP1 family.  
These transcription factors, along with NF-κB drive the expression of proinflammatory 
genes such as Il6, Cox2, and Il1b.  TRIF signaling occurs after endocytosis of TLR4:MD-
2 and is, therefore, delayed.  TRIF activates NF-κB and MAPKs through RIP1 and 
TAK1.  It also uniquely induces IRF3 activating phosphorylation and dimerization which 





Fig. 2.  Salmonella minnesota lipid A and MPLA structures.  Acid hydrolysis of S. 
minnesota LPS removes the Kdo group to yield lipid A.  Because lipid A is prepared 
from biological LPS isolates, it is composed of a mixture of congeners with different 
numbers of acyl chains (from 3 to 7).  This variability is due to inherent heterogeneity in 
the biosynthesis of LPS by the bacterium.  The hepta-acyl form is shown above.  Further 
acid hydrolysis removes the 1-phosphate of lipid A to yield MPLA.  Shown above is the 
hexa-acyl form which is presumably the most active congener.  Although the hepta-acyl 
form is removed from clinical preparations of MPL adjuvant by alkaline hydrolysis, this 





Fig. 3.  Synthetic lipid A (sLipid A) and MPLA (sMLA) structures.  The synthetically 
prepared lipid A and MPLA based on the E. coli chemotype are homogeneous, both 
bearing 6 acyl chains.  sMLA differs from sLipid A at the 1-position and at the third acyl 







Mice and reagents 
C57BL/6, TRIFlps2/lps2 and CD14-/- mice were purchased from the Jackson Laboratory. 
MyD88-/- mice were a gift of S. Akira (through R. Kedl, University of Colorado School of 
Medicine). Mice were housed in a specific pathogen-free barrier facility at the University 
of Louisville and cared for according to regulations set forth by its Institutional Animal 
Care and Use Committee.  Salmonella minnesota MPLA and lipid A (sold dissolved in 
water) were purchased from Alexis/Enzo Life Sciences. The compounds sMLA (MW 
1763.5, sold as PHAD, Cat. no. 699800, Avanti Polar Lipids), sLipid A [MW 1798.4, 
sold as Lipid A (E. coli), Cat. no. CLP-24005-s, Peptides International], and synthetic 
lipid IVa (MW 1405.7, Cat. no. CLP-24006-s, Peptides International) were dissolved by 
vortexing in 100% DMSO (Sigma-Aldrich) at 1 mg/ml and then promptly frozen in 
single use aliquots at -80°C. Agonists were serially diluted in culture medium before 
being added to cell cultures. The DMSO concentration in cell culture was ≤ 0.32%. A 
vehicle control corresponding to the highest DMSO concentration in each experiment 
(0.1 or 0.32%) was always used. Primary antibodies for the Western blotting analysis of 
the following targets were purchased from Cell Signaling Technology: pIRF3 (Ser396, 
Cat. no. 4947), pJNK (Thr183/Tyr185, Cat. no. 4668), pp38 (Thr180/Tyr182, Cat. no. 9215), 
pERK1/2 (Thr202/Tyr204, Cat. no. 4370), pcJun (Ser63, Cat. no. 9261), pMAPKAPK2 
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(Thr222, Cat. no. 3316), total p38 (Cat. no. 9212), total ERK1/2 (Cat. no. 4695), total cJun 
(Cat. no. 9165), total MAPKAPK2 (Cat. no. 3042), and IκBα (Cat. no. 4814). Primary 
antibodies for the Western blotting analysis of the following targets were purchased from 
Santa Cruz Biotechnology: IRAK1 (Cat. no. sc-5288), total IRF3 (Cat. no. sc-9082), β-
actin (Cat. no. sc-1616), and total JNK (Cat. no. sc-137018). All horseradish peroxidase 
(HRP)-conjugated secondary antibodies were purchased from Jackson ImmunoResearch. 
The JNK inhibitor SP600125 (Sigma-Aldrich) and the p38 MAPK inhibitor SB202190 
(Calbiochem) were dissolved in 100% DMSO at concentrations of 25 and 3 mM, 
respectively, and were frozen at -20°C until needed for use. The anti-mouse IFNAR1 
antibody MAR1-5A3 and the functional grade mouse IgG1 isotype control were 
purchased from Leinco Technologies. Recombinant mouse IFN-β protein was purchased 
from the PBL Interferon Source.  Recombinant mouse TNFα was purchased from 
eBioscience. 
 
Generation and culture of bone marrow-derived dendritic cells (BMDCs) 
BMDCs were prepared with a procedure modified from that of Lutz et al. (82). Briefly, 
bone marrow plugs were flushed from the femurs and tibiae of mice with sterile Hank’s 
balanced salt solution (HBSS) and resuspended in BMDC medium containing R10F 
[RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM 
L-glutamine, 1 mM sodium pyruvate, penicillin (50 U/ml), streptomycin (50 μg/ml), 50 
μM β-mercaptoethanol, and GM-CSF (5 ng/ml, Miltenyi Biotec or R&D Systems]. Bone 
marrow cells (2 × 106, excluding red blood cells) were seeded in 100-mm bacteriological 
petri dishes in 10 ml of BMDC medium and incubated at 37°C. On days 3 and 8, 10 ml of 
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BMDC medium was added to the cultures. On day 6, 10 ml of BMDC medium was 
removed and replaced with fresh medium. On day 10, non-adherent BMDCs were 
collected. BMDCs were typically > 85% CD11c+CD11b+MHCII+CD86lowCD14+CD4-
CD8-B220-CD19-GR1- as determined by flow cytometric analysis. 
 
Collection of mouse serum 
Mice were euthanized by CO2 asphyxiation.  Blood was collected in Microtainer tubes 
with a serum separator (BD) after cardiac puncture, and serum was collected after 
centrifugation.  Fully concentrated serum and serum diluted to 30% in RPMI was frozen 
at -80°C until needed. 
 
Maturation of BMDC and flow cytometry 
BMDC were seeded at 1 x 106 cells/well in 6 well plates and incubated for 2 hours at 
37°C.  TNFα or sLipid A diluted in R10F was used to activate the cells for approximately 
18 hours.  Matured BMDC were then collected using cell scrapers.  Calcium and 
magnesium free HBSS washes and versene treatment was used to facilitate cell removal.  
Cells were incubated in 20% FC receptor block (2.4.G2 supernatants) for about 10 
minutes and then stained with the following antibodies: CD11c-FITC, CD40-APC, 
CD14-APC (all from eBioscience).  CD40-APC and CD14-APC were replaced with the 
corresponding isotype control antibodies in separate tubes.  Cells were stained for 
approximately 45 min in the dark at 4°C.  Five minutes before acquiring data on the 
FACScalibur, 7AAD viability staining solution (eBioscience) was added to the cells with 
vortexing.  In ELISA experiments, BMDC were seeded in 96 well plates at 1 x 105 
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cells/well and incubated at 37°C for 2 hours.  BMDC were then activated with TNFα or 
left unactivated for about 18 hours.  The cells were then washed twice with HBSS and 
new media added to the wells.  Cells were rested for an additional 2 hours at 37°C, 
followed by activation with agonist for about 18 hours.  Supernatants were then collected 
and protein concentrations analyzed by ELISA. 
 
Intracellular phospho-protein staining 
BMDC (1 x 106) were incubated with MAR1-5A3 or media alone for 1 hour in 
polystyrene snap cap tubes.  The cells were then activated for 1 hour with 100 ng/ml 
sLipid A or DMSO as control.  Cells were then washed in ice cold HBSS and 
resuspended in cold Fc block for 10 min.  After another wash with cold HBSS, 1.5% 
formaldehyde was added to the cells slowly with vortexing.  The cells were then 
incubated for 10 at room temperature.  After washing out the formaldehyde, ice cold 
methanol was added to the cells with vortexing and the cells were incubated at 4°C for 10 
min.  The methanol was then washed out and the cells were stained with anti-pSTAT1 
(pY701)-PE (BD) or isotype control antibody.  Data was acquired on a FACScalibur. 
 
Cytokine measurement 
BMDCs (1 × 105/well) suspended in R10F medium were incubated in flat-bottom, 96-
well plates for 2 hours at 37°C before TLR4 agonists or DMSO (vehicle control) diluted 
in R10F were added. In the MAPK inhibition experiments, 10 μM SP600125, 10 μM 
SB202190, or DMSO (vehicle control) was added 30 min before addition of the TLR4 
agonists. In the IFNAR1-blocking experiments, MAR1-5A3 (10 μg/ml) or isotype control 
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antibody was added immediately before plating the BMDCs for a 2-hour pre-incubation. 
After 18 hours of stimulation with TLR4 agonists at 37°C, supernatants were collected, 
and IL-6 (BD Biosciences) and IP-10 (R&D Systems) concentrations were measured by 
ELISA, according to each manufacturer’s specifications. 
 
Quantitative real-time PCR 
BMDCs (5 × 105) suspended in R10F medium were incubated in 5-ml polystyrene round-
bottom tubes at 37°C for 2 hours before TLR4 agonists or IFN-β was added.  MAPK 
inhibitors and the IFNAR1 blocking antibody were used in the manner described earlier. 
After they were stimulated, the cells were washed with ice-cold HBSS. Cell lysis and 
total RNA isolation were performed with RNeasy plus mini kits (Qiagen) according to 
the manufacturer’s protocol, and complementary DNA (cDNA) was synthesized with 
Qscript cDNA Supermix (Quanta BioSciences). qPCR analysis was performed with a 
Bio-Rad CFX96 real-time system with Power SYBR Green PCR Mastermix (Applied 
Biosystems) and pre-optimized Quantitect primer pairs (Qiagen). Fold-increases in 
mRNA abundances in treated cells relative to those in vehicle control cells were 
calculated with the 2-ΔΔCt method, and GAPDH mRNA abundance was used for 
normalization. 
 
Western blotting analysis 
BMDCs (2.5 to 3 × 106) in R10F medium were pre-incubated for 2 hours in 5-ml 
polystyrene round-bottom tubes at 37°C, which was followed by activation with different 
concentrations of sLipid A or DMSO. After stimulation for 15 min or 1 hour, BMDCs 
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were washed with ice-cold HBSS containing 50 μM NaF. Cells were lysed with 
radioimmunoprecipitation buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM 
EDTA, 1% Triton x-100, 1% sodium deoxycholate, and 0.1% SDS] containing Complete 
Mini protease inhibitor cocktail tablets (Roche) and phosphatase inhibitor cocktail 
(Sigma), and the BCA assay (Pierce) was used to determine the protein concentrations of 
the lysates. Samples normalized for protein content were resolved by 10% SDS-PAGE. 
Proteins were transferred onto nitrocellulose membranes (GE Healthcare). The 
membranes were blocked with 5% non-fat dry milk or 5% bovine serum albumin (BSA, 
for the analysis of pIRF3 only) for 1 hour and then were incubated overnight at 4°C with 
primary antibodies in 5% BSA or 5% non-fat dry milk (for the detection of β-actin, 
IRAK1, and total IRF3 only). HRP-conjugated secondary antibodies were resuspended in 
5% non-fat dry milk and incubated with the Western blots for 1 hour. The blots were 
developed with ECL Prime (GE Healthcare) or SuperSignal ELISA Femto substrate 
(Pierce) on a Fujifilm LAS-4000 Mini, and data were quantified with Multi Gauge V3.0 
software (Fujifilm). 
 
Statistical analysis and log(EC50) measurement 
Log(EC50) values for each agonist-induced response were calculated by generating four-











Differences between logEC50 values were analyzed by unpaired two-tailed t test (for 
comparisons between two sets of genes) or by ordinary one-way ANOVA with Tukey’s 
multiple comparisons post-test (for comparisons between three or more sets of genes). 
Differences between protein production in the presence of WT or CD14KO mouse serum 
were determined with ordinary two-way ANOVA with Sidak’s multiple comparisons 
test.  TNFα-induced upregulation of CD14 surface expression was analyzed by a paired 
two-tailed T test.  Statistically significant inhibition of increases in mRNA abundance by 
MAPK inhibitors was determined with repeated measures two-way ANOVA with 
Dunnett’s multiple comparison post-test. Ordinary two-way ANOVA analysis with 
Sidak’s multiple comparisons post-test was used to analyze the effects of MAPK 
inhibitors on gene logEC50s, and to compare IFNβ vs sLipid A-induced time courses. 
Differences in the logEC50 values in the IFNAR1-blocking experiments were analyzed 




THE CONTRIBUTION OF CD14 TO MYD88- AND TRIF-ASSOCIATED 
RESPONSES ELICITED BY BIOLOGICAL MPLA AND LIPID A 
 
INTRODUCTION 
 The quality of the cellular response to a TLR4 agonist depends not only upon the 
structural characteristics of the agonist itself, but also upon the presence of the TLR4 co-
receptor CD14.  Like the TLRs, CD14 is a member of the LLR family of proteins (83).  It 
is expressed in varying abundance as a GPI-anchored surface protein (called membrane-
bound or mCD14) (12) on certain non-myeloid and myeloid cells including endothelial 
and epithelial cells, monocytes, macrophages, dendritic cells, and granulocytes (84).  In 
addition, CD14 is found in a soluble form (sCD14) in the serum and is thought to be 
released by enzymatic cleavage of mCD14 or cellular secretion (25).  Its structure is that 
of a curved solenoid which forms an N-terminal hydrophobic ligand-binding pocket with 
peripheral cationic amino acid residues (85).  The ligand-binding pocket is deep and 
flexible (85), presumably allowing CD14 to bind a variety of different molecules 
including LPS (9), peptidoglycan (86), and lipoteichoic acid (87).  Interaction between 
hydrophobic patches at the C-termini cause CD14 to form a horseshoe-like homodimer 
(85). 
A major role of CD14 is to enhance TLR4 activity in response to low 
concentrations of LPS.  Initially, LBP in the serum extracts LPS monomers from either 
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bacterial membranes or smaller aggregates and catalytically transfers them to CD14 (23, 
24).  CD14 then loads monomeric LPS into the binding pocket of MD-2 associated with 
TLR4 which promotes TLR4/MD2 heterotetramerization and intracellular signaling (88, 
89).  Both mCD14 and sCD14 are capable of this process, and sCD14 may be especially 
important for TLR4 responsiveness in cell types that express little if any mCD14 such as 
human umbilical vein endothelial cells (90, 91).  If extracellular concentrations of LPS 
are very high, TLR4 is activated independently of CD14 (15). 
In addition to its function as an LPS transport protein, CD14 was shown to be 
actively involved in the TRIF-dependent signaling pathway of TLR4.  Early work by 
Perera et al. supported the existence of unique CD14-dependent and CD14-independent 
pathways in the response of macrophages to LPS even before the discovery of TLR4 
(15).  In this study, CD14-deficient macrophages expressed minimal TRIF-dependent 
Ip10 mRNA compared to WT macrophages at high LPS concentrations.  At these same 
agonist doses, MyD88-associated Il1b and Tnfa expression was unaffected by CD14-
deficiency.  Jiang et al. (92) were the first to make a direct connection between CD14 and 
TRIF signaling, demonstrating that CD14-deficient mouse macrophages were defective 
in TRIF-dependent type I IFN production in response to smooth (containing O-antigen) 
and rough (lacking O-antigen) LPS chemotypes, but were largely unaffected in MyD88-
associated TNFα production in response to rough LPS.  Later, Zanoni et al. (47) 
elaborated on this work, confirming the dependence of TRIF signaling on CD14, but also 
showing that CD14 itself directs the endocytosis of TLR4, independent of TLR4-induced 
signaling events.  Therefore, TRIF signaling, which is initiated from an endocytic 
compartment (50), is weak in the absence of CD14 because TLR4 endocytosis is minimal 
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under these conditions.  Presumably, CD14 controls endocytosis of TLR4 through an 
immunoreceptor tyrosine-based activation motif (ITAM)-mediated event that then 
activates PLCγ2 and Syk (47). 
Several groups have reported that certain TLR4 agonists may have a reduced 
requirement for CD14-dependent TLR4 stimulation (72, 93, 94).  MPLA has been placed 
in this category (72, 93).  Blocking CD14 on the surface of human monocyte-derived DC 
had no effect on MPLA-induced IL-12p40 secretion, although the use of very high doses 
of MPLA may have biased these experiments (72).  In addition, Tanimura et al. (93) 
showed that TNFα production by CD14-deficient mouse BMDC in response to MPLA 
was not reduced when compared to WT BMDC.  On the other hand, this same study 
concluded that CD14 was required for MPLA-induced heterotetramerization and 
endocytosis of TLR4/MD2, suggesting that MPLA may engage CD14 and require its 
presence for full activity.  Therefore, there is still some confusion concerning the extent 
to which MPLA requires CD14 to stimulate TLR4 and to the specific responses that 
MPLA can elicit independently of CD14. 
We previously published that MPLA was a TRIF-biased agonist in mouse, both in 
vitro and in vivo (77), but the mechanism by which this occurs has not been fully 
revealed.  One hypothesis is that MPLA interacts with TLR4:MD-2 or CD14 in a 
fundamentally different manner than LPS or lipid A, which allows the TRIF pathway to 
be more completely engaged while MyD88 signaling remains weak.  Given that mCD14 
expression is linked to TLR4 endocytosis and TRIF signaling, we sought to determine the 
extent to which CD14 ablation affects TRIF-dependent and MyD88/TRIF co-dependent 
responses to MPLA and lipid A in mouse DC.  High and low concentrations of these 
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agonists were tested to fully assess the degree to which both pathways are affected.  In 
this study, MPLA did not induce a TRIF-biased response profile in WT BMDC.  Instead, 
MPLA was less potent than lipid A in stimulating both TRIF- and MyD88 and TRIF-co-
dependent outcomes.  Tests in WT and CD14-deficient BMDC did not reveal obvious 
differences between MPLA and lipid A requirements for CD14 for either TRIF- or co-
dependent signaling events.  Therefore, variations in the interaction of MPLA or lipid A 
with CD14 in the TLR4 receptor complex are unlikely to explain any TRIF-bias by 
MPLA in mouse. 
 
RESULTS 
MPLA is not a TRIF-biased agonist in mouse dendritic cells. 
 In previous experiments, we characterized MPLA as a TRIF-biased agonist by 
comparing the inflammatory response of mouse macrophages (thioglycolate-elicited or 
bone marrow-derived) to MPLA or LPS, or by measuring inflammatory outcomes in vivo 
(77).  The roles of macrophages and DC differ during the response to an infection.  
Macrophages are critical in the initial control of pathogens while DC specialize in antigen 
presentation in lymph nodes.  Therefore, it is plausible that these cells’ responses to 
MPLA may differ.  In order to determine whether MPLA is a TRIF-biased agonist in DC, 
BMDCs were exposed to different concentrations of MPLA and lipid A, followed by 
measurement of MyD88- and TRIF-co-dependent or TRIF-dependent gene products.  
MPLA induced co-dependent IL-6 protein production and Cox2 mRNA more weakly 
than did lipid A, confirming our previous results (77) (Fig. 4A).  Surprisingly, MPLA 
was also less potent than lipid A in inducing TRIF-dependent Ifit1 mRNA, a response the 
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two agonists induced equivalently in previous experiments (77) (Fig. 4B).  To 
quantitatively determine the extent of MPLA’s potency deficit for each analyte, we used 
non-linear regression to fit curves to the data points, allowing the estimation of each 
agonist’s log(EC50) values.  Lipid A was approximately 30 times more potent than 
MPLA for both TRIF- and co-dependent gene products, indicating no obvious biases in 
adaptor signaling by MPLA [log(EC50) values for lipid A: IL-6 = 0.86; Cox2 = 1.17; 
Ifit1 = 1.19; log(EC50) values for MPLA: IL-6 = 2.33; Cox2 = 2.67; Ifit1 = 2.97].  These 
results indicate that MPLA is not a TRIF-biased agonist in mouse BMDC. 
 
MyD88- and TRIF-co-dependent responses are reduced at low concentrations of MPLA 
and lipid A in CD14-deficient BMDCs. 
 Regardless of the fact that MPLA did not behave as a TRIF-biased agonist in 
BMDC, we compared the responses of MPLA and lipid A in WT and CD14KO BMDCs 
to determine whether one of these agonists exhibited a greater dependence on CD14 to 
induce signaling outcomes downstream of MyD88 or TRIF.  Several studies have shown 
that induction of MyD88- and TRIF-co-dependent genes like Tnfα in CD14-deficient 
cells is reduced in response to low concentrations (less than 1000 ng/ml) of LPS (15, 47, 
95).  We activated WT and CD14KO BMDCs with different concentrations of MPLA or 
lipid A in medium containing mouse serum collected from CD14KO mice.  This allowed 
us to focus solely on mCD14’s contribution to TLR4 signaling because sCD14 was 
absent from the system. 
Phenotyping by flow cytometry demonstrated that WT and CD14KO BMDCs 
expressed an equivalent surface abundance of CD11c, CD86, and MHCII.  The 
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expression of both CD86 and MHCII was low indicating an immature phenotype (Fig. 5).  
MyD88- and TRIF-co-dependent IL-6 protein abundance in culture supernatants, 
measured after 6 hours activation, was reduced in CD14KO versus WT BMDC activated 
with lipid A concentrations below 1000 ng/ml (Fig. 6A).  Similarly, IL-6 production was 
reduced in CD14KO BMDC activated with MPLA concentrations below 10,000 ng/ml 
(Fig. 6B).  Co-dependent Cox2 mRNA measured 2 hours after activation followed the 
same pattern as IL-6 when induced with either agonist (Fig. 6 A and B). 
In order to estimate the decrease in potency of lipid A and MPLA in the absence 
of mCD14, we compared the agonist concentrations required to induce equivalent 
expression of IL-6 protein or Cox2 mRNA in WT or CD14KO BMDC.  Calculation of 
agonist log(EC50) values by non-linear regression was not possible in this case because 
the concentrations of agonist need to produce a plateau in the dose response curves were 
not feasible.  Equivalent production of IL-6 protein and expression of Cox2 mRNA was 
induced by 100 ng/ml lipid A in WT BMDC and 1000 ng/ml lipid A in CD14KO BMDC 
(Fig. 6A), a 10 fold difference.  Similarly, approximately 10 times more MPLA was 
needed to induce maximal IL-6 and Cox2 in CD14KO BMDC.  Similar expression levels 
of IL-6 and Cox2 were induced by 1000 ng/ml and 100 ng/ml in CD14KO and WT 
BMDC, respectively (Fig. 6B).  Therefore, it is likely that mCD14 contributes similarly 






TRIF-dependent responses are reduced at both high and low concentrations of lipid A 
and MPLA in CD14-deficient BMDCs. 
 TRIF-dependent responses like type I IFN production and the induction of type I 
interferon-inducible genes has been shown to be severely decreased by the absence of 
mCD14 (15, 47, 92, 93).  In order to determine whether MPLA differed from lipid A in 
its requirement for mCD14 for TRIF-dependent signaling events, we compared MPLA- 
and lipid A-induced Ifit1 mRNA expression in WT and CD14KO BMDC.  Ifit1 mRNA 
expression was reduced in CD14KO BMDC compared to WT over all doses of lipid A 
and MPLA tested.  Although a very high dose of lipid A (10,000 ng/ml) was unable to 
completely compensate for the lack of mCD14, approximately 50% of maximum Ifit1 
mRNA expression was retained (Fig. 7).  In contrast, MPLA-induced Ifit1 mRNA 
expression remained very low over all doses (Fig. 7).  These results confirm that optimal 
TRIF-dependent TLR4 signaling is dependent upon mCD14 expression.  The lack of 
complete dose response curves in these experiments made it difficult to conclude that 
MPLA and lipid A differ in their dependence on mCD14 for TRIF-dependent signaling.  
Similar Ifit1 mRNA expression was induced by 1000 ng/ml and 10 ng/ml lipid A in 
CD14KO and WT BMDC, respectively.  Similar expression was induced by 10,000 
ng/ml and 100 ng/ml MPLA in CD14KO and WT BMDC, respectively.  Therefore, the 
decrease in potency of both agonists in the absence of CD14 may be about 100 fold.  The 
apparent weakness in MPLA’s ability to induce Ifit1 compared to lipid A in CD14KO 





BMDC culture in serum from wild-type mice has no effect on IL-6 production. 
 Previous studies have shown that sCD14 can partially rescue MyD88-associated 
responses in CD14KO macrophages (92, 96).  In contrast, only mCD14 seems to be able 
to rescue TRIF-dependent responses such as IFNβ production (97).  In certain cases, 
sCD14 may also inhibit the response to LPS, presumably by sequestering it from 
TLR4:MD2 (98, 99).  It is unknown whether lipid A or MPLA have differential abilities 
to utilize sCD14 in order to enhance TLR4 signaling.  Therefore, we asked whether 
sCD14 in WT mouse serum could rescue the IL-6 response to lipid A or MPLA.  WT and 
CD14KO BMDC were cultured in media containing the serum collected from WT and 
CD14KO mice, and activated with different concentrations of MPLA or lipid A.  
Activation in WT, sCD14 replete, serum had no significant effect on the IL-6 response to 
either agonist in WT or CD14KO BMDC (Fig. 8).  Because we were unable to 
demonstrate a restoration of the IL-6 response with the addition of WT serum in CD14-
deficient BMDC, we could not make a conclusion about MPLA or lipid A’s ability to 
utilize sCD14. 
 
Maturation of BMDC does not enhance MyD88- and TRIF-co-dependent or TRIF-
dependent responses. 
 During the completion of the experiments presented above, we also discovered 
that a sMLA (Fig. 3) which we had also proposed was a TRIF-biased agonist (78, 79), 
was not behaving as a true TRIF-biased agonist over a complete concentration range 
(discussed in Chapter IV).  We wondered if some unintentional phenotypic drift had 
occurred in our BMDC cultures over time that had caused TRIF-bias to disappear.  One 
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such difference could be the maturation state of the cells.  BMDCs matured with TNFα 
were shown to upregulate mCD14 expression, in addition to costimulatory molecules 
(47).  Higher mCD14 surface expression correlated with faster and more robust 
internalization of TLR4, and with secretion of larger amounts of TRIF-dependent type I 
IFN in response to stimulation with LPS.  MyD88- and TRIF-co-dependent TNFα, on the 
other hand, was unaffected (47).    Therefore, we hypothesized that monophosphorylated 
agonists would exhibit greater TRIF-bias if used to activate matured BMDC. 
BMDC were matured with TNFα for 18 hours and then activated with different 
doses of sMLA or sLipid A for an additional 18 hours.  A clear increase in BMDC CD40 
expression occurred upon TNFα treatment indicating maturation (Fig. 9).  As predicted, 
mCD14 expression also increased, although this increase did not score as significant (p = 
0.0834).  Unexpectedly, TNFα maturation decreased production of TRIF-dependent IP-
10 in response to low doses of sMLA or sLipid A (Fig. 10B).  Co-dependent IL-6 was 
largely unaffected by TNFα maturation (Fig. 10A).  Therefore, maturation and increased 
surface expression of mCD14 did not promote sMLA TRIF-bias by selectively enhancing 
the TRIF-dependent gene product IP-10. 
 
DISCUSSION 
A major goal has been the elucidation of a mechanism for TRIF-biased TLR4 
signaling since we proposed that MPLA’s TRIF-bias allowed it to retain beneficial 
effects on adaptive priming without major toxicity (77).  We now know that MPLA and 
sMLA only weakly induce heterotetramerization of TLR4:MD-2, which explains why 
they are defective in MyD88-associated signaling events such as IRAK-1 activation (81).  
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Even so, these compounds can induce some MyD88 signaling, which may be beneficial 
in certain cases (77, 80).  The aim of this work was to narrow the gap in our 
understanding of how MPLA is able to retain robust TRIF-dependent signaling alongside 
weak MyD88-dependent signaling.  We reasoned that a mechanism could be in place that 
boosts MPLA-induced TRIF-dependent signaling despite its weakness in induction of 
TLR4:MD-2 heterotetramerization.  A stronger dependence on, or perhaps interaction 
with, CD14 that promotes TRIF signaling was hypothesized to drive MPLA’s TRIF-bias.  
Therefore, removal of CD14 from the cell system was expected to have a much greater 
impact on MPLA’s versus lipid A’s ability to induce both co-dependent and TRIF-
dependent gene products. 
Interpretation of the results of this study was made difficult by the fact that MPLA 
did not behave as a TRIF-biased agonist in BMDC over the doses tested (Fig. 4).  
Comparison of the lipid A and MPLA log(EC50) values for co-dependent IL-6 protein 
and Cox2 mRNA, and TRIF-dependent Ifit1 mRNA, clearly demonstrated that lipid A 
was about 30 times more potent than MPLA in both pathways (Fig. 4).  Despite its 
potency deficit, MPLA was able to induce the same maximum response in all analytes 
tested, indicating that the two agonist share the same efficacy.  Therefore, MPLA is not a 
partial agonist in the mouse BMDC system. 
There are at least two ways to explain this observation.  First, the TLR4:MD-2 
heterotetramerization that MPLA is capable of inducing may be as efficient as that of 
lipid A in the recruitment of downstream signaling adaptors.  In this case, MPLA’s low 
potency would be explained by a lower affinity for the receptor.  Second, MPLA may 
induce TLR4:MD-2 heterotetramerization in a conformation that less efficiently recruits 
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signaling adapters, but that is capable of inducing a maximal response given the presence 
of enough receptors on the cell surface.  In this case, the affinities of MPLA and lipid A 
for TLR4:MD-2 could be comparable. 
We were unable to pinpoint the exact reason why MPLA did not exhibit TRIF-
bias in these experiments.  TRIF-dependent IP-10 production was not selectively 
enhanced by pre-stimulation with TNFα that caused increased mCD14 expression on 
BMDC (Figs. 9 and 10), indicating that mature DC are not more likely to engage in 
TRIF-biased signaling versus immature DC. 
A second reason for the lack of TRIF-bias by MPLA could be due to the use of 
BMDC instead of macrophages.  As noted above, MPLA was initially characterized as a 
TRIF-biased agonist in macrophages.  Activated macrophages at an infection site play a 
role in potentiating the inflammatory response and then contribute to anti-inflammatory 
resolution, such as wound healing.  On the other hand, activated dendritic cells become 
potent antigen presenting cells and acquire the ability to home to secondary lymphoid 
organs.  Therefore, the nature of the inflammatory response to MPLA by these two cell 
types could very well be different and reflect their unique physiological function (100).  
Recent work by Ling et al. (101) demonstrated that CD11b expression in DC, but not in 
macrophages, regulates LPS-induced TLR4 endocytosis, and MyD88- and TRIF-
dependent TLR4 signaling.  Interestingly, TRIF signaling outcomes in BMDC required 
CD11b expression even when LPS-induced TLR4 internalization was rescued by mCD14 
upregulation by CpG treatment.  Therefore, differences between DC and macrophage 
responses to LPS, especially in the TRIF-dependent pathway, may be important. 
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Despite a lack of TRIF-bias, we were still able to assess the level of dependence 
of MPLA and lipid A on mCD14.  Approximately 10 times more lipid A or MPLA was 
needed to induce equivalent MyD88/TRIF co-dependent IL-6 protein and Cox2 mRNA 
induction in CD14KO BMDC (Fig. 6), suggesting that MPLA and lipid A utilize mCD14 
in a similar fashion.  Soluble CD14 seemed to play a negligible role in this system 
because the use of WT serum had no effect on IL-6 production (Fig. 8).  These results do 
not support the conclusion of Tanimura et al. (93), who showed that MPLA can induce 
co-dependent TNFα protein independently of mCD14 at low doses.  The influence of 
mCD14 on the MyD88-dependent pathway is linked to its transport of agonist to and 
loading of TLR4:MD-2; therefore, we speculate that mCD14 has a similar affinity for 
MPLA and lipid A. 
Neither lipid A nor MPLA were capable of inducing maximal TRIF-dependent 
Ifit1 mRNA expression, even at very high doses (Fig. 7).  These data confirm the strong 
dependence of TRIF-dependent signaling on mCD14 (47, 92, 93).  MPLA induced 
minimal Ifit1 mRNA in the absence of mCD14 when compared to lipid A, which could 
lead to the conclusion that MPLA does indeed have a stronger dependence upon the 
coreceptor.  But this might also be due to MPLA’s low potency, in which case a higher 
MPLA dose might induce Ifit1 mRNA levels comparable to lipid A.  Given the similar 
dependence of MPLA and lipid A on mCD14 for MyD88 activity, the latter explanation 
is more plausible. 
The fact that in CD14KO BMDC, lipid A was capable of inducing up to 50% of 
the maximal TRIF-dependent Ifit1 mRNA expressed in WT BMDC (Fig. 7) demonstrates 
that CD14 is not absolutely required for TRIF signaling and that a CD14-independent 
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mechanism is also involved.  Such a CD14-independent process has already been 
described in DC, whereby a TLR4 agonist in the form of large, particulate phagocytic 
cargo (i.e. whole E. coli) can induce TLR4 endocytosis and type I IFN production in 
CD14KO DC (47).  Alternatively, scavenger receptor-mediated uptake may provide a 
means of delivering TLR4 agonists to the endocytic compartment where TRIF signaling 
can proceed (102). 
In conclusion, this chapter provides evidence to support the claim that a unique 
interaction or utilization of CD14 by MPLA is not responsible for the difference between 
its signaling profile and that of native lipid A.  Rather, MPLA is likely a weak agonist of 
TLR4 in mouse BMDC.  As explored in Chapter IV, observation of a TRIF-biased 
response by MPLA is likely related to cross-talk between TLR4 and the type I IFN 
receptor.  In addition, this work supports a qualification of the notion that mCD14 directs 
endocytosis of TLR4/MD2 and TRIF-dependent signaling.  We suggest the existence of a 
CD14-independent pathway that drives appreciable TRIF-dependent signaling in 






Fig. 4.  MPLA is not a TRIF-biased agonist in mouse BMDCs.  WT BMDCs were 
activated with the indicated concentrations of MPLA or lipid A in media containing 1 to 
3% serum collected from CD14-deficient mice.  (A, left) After 6 hours activation, culture 
supernatants were measured for IL-6 protein abundance by ELISA.  Steady-state 
abundance of Cox2 mRNA (A, right) and Ifit1 mRNA (B) relative to control (water) 
treated samples was measured after 2 hours activation by qPCR.  The fold increase over 
control was measured in triplicate and converted to a percentage of maximum fold 
increase within each independent experiment.  Log(EC50) values were calculated by 4-





Fig. 5.  WT and CD14-/- BMDC are phenotypically similar.  WT and CD14KO 
BMDCs were stained with fluorochrome-conjugated antibodies against CD11b, CD11c, 
MHCII (I-A/I-E), GR1, CD86, and CD14.  Data were acquired using a FACScalibur and 





Fig. 6.  MPLA and lipid A utilize CD14 similarly to induce expression of MyD88- 
and TRIF-co-dependent genes.  WT and CD14KO BMDC were activated with the 
indicated concentrations of (A) lipid A or (B) MPLA in media containing 1 to 3% serum 
from CD14KO mice.  IL-6 protein in culture supernatants was measured after 6 hours 
activation by ELISA.  The fold increase in abundance of steady-state Cox2 mRNA 
relative to vehicle treated cells was measured by qPCR after 2 hours activation.  Data are 
the mean ± SD of triplicate samples.  An experiment representative of at least 3 




Fig. 7.  MPLA and lipid A both require CD14 for optimal TRIF-dependent gene 
expression.  WT and CD14KO BMDC were activated with the indicated concentrations 
of lipid A or MPLA in media containing 1 to 3% serum from CD14KO mice.  The fold 
increase in abundance of steady-state Ifit1 mRNA relative to vehicle treated cells was 
measured by qPCR after 2 hours activation.  Data are the mean ± SD of triplicate 




Fig. 8.  Serum collected from WT mice does not rescue IL-6 production in response 
to MPLA or lipid A.  BMDC derived from WT and CD14KO mice were activated for 6 
hours with the indicated concentrations of lipid A (left) or MPLA (right) in media 
containing 1 to 3% serum collected from WT or CD14KO mice.  IL-6 protein abundance 
in culture supernatants was measured by ELISA.  Data are the mean ± SEM of 3 
independent experiments.  Data were not significant by two-way ANOVA with Sidak’s 




Fig. 9.  Upregulation of mCD14 expression on BMDCs by TNFα-induced 
maturation.  WT BMDC were treated with 10 ng/ml TNFα, 100 ng/ml slipid A, or 
vehicle control (NT) for 18 to 19 hours.  BMDC were then stained with APC-conjugated 
anti-CD14, APC-conjugated anti-CD40, or the corresponding isotype controls.  Data 
were collected on a FACScalibur and analyzed with Flowjo software.  (Right) The 
geometric mean of surface CD14 was compared between untreated and TNFα treated 
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cells.  Data are the mean ± SEM of 5 independent experiments.  Statistics were 




Fig. 10.  Increased surface expression of mCD14 does not preferentially enhance 
TRIF-dependent protein production.  WT BMDC were treated with 10 ng/ml TNFα or 
left untreated for 18 to 19 hours and then activated with the indicated concentrations of 
sLipid A or sMLA for an additional 18 hours.  (A) IL-6 and (B) IP-10 protein abundance 





AUTOCRINE AND PARACRINE SIGNALING BY TYPE I INTERFERONS 
CONTRIBUTES TO TOLL-LIKE RECEPTOR 4 TRIF-BIAS 
 
INTRODUCTION 
 In general, the TRIF signaling pathway is more associated with the initiation of 
adaptive immune responses than is the MyD88 signaling pathway, which is more 
commonly associated with proinflammatory outcomes.  For example, TRIF-deficiency in 
mice substantially impairs the induction of antigen-specific T cell proliferation by APCs, 
whereas MyD88-deficiency has little effect on this process (77, 103).  This impairment 
arises partly because IFN-β production absolutely requires the activation of IRF3 through 
TRIF (52, 55).  IFN-β is essential for the adjuvant effects of several TLR agonists on T 
cell priming, including TLR4 (103), which may be due to the ability of IFN-β to drive 
upregulation of costimulatory molecules and MHCII on APCs (104, 105).  In one study, 
the TLR3 agonist polyI:C was the best of a panel of adjuvants, including LPS, at 
inducing antigen-specific Th1 CD4 responses because it induced the most robust type I 
IFN response (106).  In addition, type I IFN promotes antigen cross-presentation (107) 
and T cell survival (108).  TRIF signaling is also linked to adaptive immunity through 
TRIF-dependent chemokines, such as IP-10 (CXCL10), which promote the recruitment 
of T cells to DC for priming (109). 
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 Because TLR4 is the only TLR to signal through both MyD88 and TRIF, it is the 
only TLR with the potential for adapter modulation, the ability to signal more strongly 
through one adapter compared to the other.  Given the distinct processes primarily 
controlled by each pathway, we and other groups have studied whether defined 
differences in agonist structure can cause MyD88- or TRIF-biased responses at the level 
of producing distinctive gene profiles (77-79, 110-112).  As noted above, we previously 
proposed that the success of MPL adjuvant was related to its ability to function as a 
TRIF-biased agonist of TLR4, which is favorable for vaccination by limiting pro-
inflammatory endpoints more than it limits those involved in T cell priming (77).  Those 
studies were performed with a research grade version of MPL adjuvant (MPLA).  In 
addition to MPLA, which is a mixture of monophosphorylated Salmonella minnesota 
lipid A species differing in numbers of acyl chains (Fig. 2), we also studied synthetic 
MPLA (sMLA), a single hexa-acyl species based on the E. coli lipid A structure (Fig. 3).  
We concluded that sMLA was also TRIF-biased in mouse cell systems (78, 79). 
 TLR4 adapter modulation is a controversial topic.  Some have questioned its 
existence citing the use of heterogeneous compounds and insufficient doses as 
confounding factors that make it impossible to draw useful conclusions about structure-
activity relationships (113).  Here, we compared the potencies of sMLA and its 
diphosphorylated counterpart synthetic Lipid A (sLipid A) (Fig. 3) in inducing the 
expression of a panel of TRIF-dependent or MyD88-associated genes (all of which are 
MyD88- and TRIF-co-dependent) in mouse BMDCs.  None of the analytes we have 
tested to date appear to be truly TRIF-independent (MyD88-sufficient) (45, 59, 60).  We 
evaluated IP-10, IFIT-1, and CD86 as representative TRIF-dependent gene products, 
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because TRIF alone is sufficient to induce the expression of the corresponding genes, 
whereas we evaluated IL-6, Cox-2, and CD80 as MyD88- and TRIF-co-dependent gene 
products, because optimal expression of the corresponding genes require both adaptor 
pathways.  We found that TRIF-bias was not unique to sMLA as judged by 
pharmacological potency.  Instead, expression of TRIF-dependent genes was induced 
with substantially less agonist than was required for the expression of MyD88- and TRIF-
co-dependent genes.  Together, these data suggest that the TLR4 signaling network is 
itself biased toward TRIF-dependent events. 
 
RESULTS 
sMLA is not a TRIF-biased agonist as assessed by pharmacological measurements 
To quantitatively evaluate sMLA as a TRIF-biased agonist, we activated BMDC 
with an extensive dilution series of sMLA or sLipid A and measured these agonists’ 
potencies using a panel of TRIF-dependent and MyD88- and TRIF-co-dependent gene 
products by log(EC50) calculation, a pharmacological method.  As expected, sLipid A 
was more potent than sMLA at inducing the expression of the MyD88- and TRIF-co-
dependent genes Il6 and Cox2 (Fig. 11A).  However, sLipid A was also more potent than 
sMLA at inducing expression of the TRIF-dependent genes Ip10 and Ifit1 (Fig. 11A).  
We compared the log(EC50) values of sLipid A and sMLA for each analyte to determine 
whether adapter bias was present despite obvious differences in agonist potency.  We 
found that sLipid A was approximately 10 fold more potent than sMLA at inducing the 
expression of both co-dependent and TRIF-dependent genes, regardless of whether they 
were measured early (steady-state mRNA at 4 hours) or late (secreted protein at 18 hours) 
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(Fig. 11, A and B).  Therefore, sMLA was not functioning as a true TRIF-biased agonist 
compared to sLipid A because sMLA’s deficiencies in potency were the same for 
indicators of both adapter pathways. 
To determine whether our experimental system (cells and agonists) had changed 
since our initial experiments using sMLA, we directly compared agonist concentrations 
similar to those explored in our previous studies of TRIF-bias (78).  We found that 
sMLA-stimulated BMDC induced lower amounts of MyD88- and TRIF-co-dependent 
IL-6 and equivalent amounts of TRIF-dependent IP-10 in culture supernatants compared 
to sLipidA (Fig. 11C), consistent with TRIF-biased signaling occurring over these doses.  
Therefore, these results were not fundamentally different from those in our previous 
studies. 
 
The expression of TRIF-dependent genes is activated with less agonist than is required to 
activate the expression of MyD88- and TRIF-co-dependent genes 
Although sMLA was a weak agonist for both co-dependent and TRIF-dependent 
genes, as measured by log(EC50)s, Figures 11A and 11C demonstrated that there were 
distinct concentrations at which sMLA was equivalent to sLipid A in induction of TRIF-
dependent genes, but that sMLA was also weaker in induction of co-dependent genes.  
One explanation for this trend is that TRIF-dependent genes are more “easily” triggered 
than co-dependent genes; more agonist is required to stimulate TLR4-induced co-
dependent events than is required for TRIF-dependent events.  To test this hypothesis, we 
compared the log(EC50) values of sMLA or sLipid for the activation of TRIF-dependent 
and co-dependent signaling events, and expected the log(EC50) values for TRIF-
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dependent events to be lower than those for co-dependent events.  As expected, the 
log(EC50) values of sMLA or sLipid A for TRIF-dependent IP-10 protein production 
was lower than their corresponding log(EC50) values for co-dependent IL-6 protein 
production (Fig. 12A).  Similarly, the log(EC50) values of sLipid A and sMLA for TRIF-
dependent mRNA responses were lower than the log(EC50) values for co-dependent 
mRNA responses (Fig. 12A).    These results suggest that in mouse BMDC, weak TLR4 
agonists such as sMLA can appear to be TRIF-biased because expression of TRIF-
dependent genes is induced more effectively with less agonist than is the expression of 
co-dependent genes. 
Both sMLA and sLipid A are hexa-acylated lipid A molecules, differing only in 
the presence or absence of the 1-phosphate of the diglucosamine head group and by 2 
carbons on one of the secondary acyl chains (Fig. 3).  Because the potential for a lipid A 
molecule to elicit the production of various cytokines is affected by both the number and 
length of its acyl chains (114, 115), it is possible that efficient activation of TRIF-
dependent signaling events at low doses of agonist may be unique to these hexa-acylated 
molecules.  To determine whether the relative ease of activating TRIF-dependent events 
was common to agonists with markedly different structures, we stimulated BMDCs with 
tetra-acylated molecule lipid IVa and measured the log(EC50) values for TRIF-dependent 
IP-10 and co-dependent IL-6 production.  Lipid IVa is an agonist of mouse TLR4, but an 
antagonist of human TLR4 (116, 117).  Similar to sMLA, Lipid IVa was less potent than 
sLipid A in stimulating production of both IP-10 and IL-6 (Fig. 12B).  As was seen with 
hexa-acylated sMLA and sLipid A, lipid IVa induced TRIF-dependent IP-10 production 
with a log(EC50) value that was significantly lower than its co-dependent IL-6 log(EC50) 
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value (Fig. 12B).  This result suggests that robust activation of TRIF-dependent events at 
low agonist doses may be intrinsic to TLR4 and less dependent on TLR4 agonist 
structure. 
 
Cd86 mRNA expression is increased with less agonist than is required to increase Cd80 
mRNA expression 
Our characterization of TLR4 agonist potencies for TRIF and MyD88- and TRIF-
co-dependent event induction was initially focused on genes encoding proinflammatory 
cytokines and chemokines.  In addition to the release of these mediators, DC function is 
inextricably linked to the upregulation of costimulatory molecules that promote adaptive 
immunity via T cell priming.  We and others described previously the TLR4 adapter 
requirements for the upregulation of the costimulatory molecules CD80 and CD86 in 
mouse DC subsets in vivo, with CD86 upregulation appearing to be dependent on TRIF 
alone and CD80 upregulation dependent on both MyD88 and TRIF (103, 118).  To 
confirm the specific adapter dependence of CD86 and CD80 in BMDCs, we generated 
BMDC from WT, TRIFLps2/Lps2 (which contain a non-functional mutation in the TRIF 
protein), or MyD88-/- mice, treated them with sLipid A, and measured increases in Cd80 
and Cd86 mRNA abundance by qPCR analysis.  The ability of sLipid A to induce 
increases in Cd86 mRNA abundance was reduced in cells in which TRIF signaling was 
inhibited, whereas its ability to induce increases in Cd80 mRNA abundance was reduced 
by the absence of either TRIF or MyD88 signaling (Fig. 13A).  These results confirm that 
in BMDCs the expression of Cd86 is TRIF-dependent, while the expression of Cd80 is 
MyD88- and TRIF-co-dependent. 
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Because TLR4 signaling-induced increases in Cd86 mRNA abundance are strictly 
TRIF-dependent, whereas increases in Cd80 mRNA are MyD88- and TRIF-co-
dependent, we hypothesized that sLipid A would have a higher potency for induction of 
Cd86 expression than for Cd80 expression.  When BMDC were treated with increasing 
concentrations of sLipid A, the log(EC50) value for increased Cd86 mRNA abundance 
was significantly lower than that for Cd80 mRNA (Fig. 13B), suggesting that the TRIF-
dependent expression of Cd86 was more easily induced than was the co-dependent 
expression of Cd80.  Therefore, the enhanced potency of TLR4 agonists for TRIF-
dependent gene expression may pertain to a variety of gene subsets with different roles in 
the immune response. 
 
The low log(EC50) values of sLipid A for the expression of TRIF-dependent genes are not 
explained by TRIF adaptor selectivity 
One potential explanation for the low log(EC50) values of TLR4 agonsits for 
TRIF-dependent genes is that comparatively more TRIF adapter engagement than 
MyD88 engagement is triggered immediately downstream of TLR4 dimerization at 
limiting doses of agonist.  To test this hypothesis, we measured the potency of sLipid A 
to activate IRF3 and IRAK1 (Fig. 14A), two signaling proteins that mediate the TRIF and 
MyD88 pathways, respectively (36, 48).  The log(EC50) values for IRF3 activating 
phosphorylation and IRAK1 disappearance, which is due to an increase in molecular 
weight from Lys63 polyubiquitination upon signaling (38, 119), were not significantly 
different when measured in 4 independent experiments (Fig. 14B).  In two paired 
experiments, the log(EC50) values for IRF3 phosphorylation were greater than those for 
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IRAK1 disappearance (Fig. 14B).  These data suggest that initial TRIF signaling is not 
induced more efficiently than initial MyD88 signaling at suboptimal TLR4 agonist 
concentrations; indeed, MyD88 signaling may be triggered more easily than TRIF 
signaling.  Therefore, the low log(EC50) values of TLR4 agonists for the production of 
TRIF-dependent gene products cannot be explained by dose-dependent TRIF selectivity 
at the level of initial adapter engagement. 
 
The log(EC50) values of sLipid A for the activation of MAPKs and NF-κB are different 
Because simple TLR4 TRIF adapter bias did not seem to explain the low 
log(EC50) values of TLR4 agonists for TRIF-dependent events, we explored signaling 
mediators that are activated through both the TRIF and MyD88 pathways.  TLR4-
induced gene expression is controlled by NF-κB and transcription factors activated by 
MAPK signaling cascades, and considerable crosstalk exists between the MyD88 and 
TRIF signaling pathways in their activation.  For example, TRIF signaling enhances NF-
κB activity, a canonical MyD88-dependent event, through a Rip1-mediated pathway (57).  
In addition, signaling through both TRIF and MyD88 contribute to MAPK activation (44, 
46).  TLR4-induced genes have varying MAPK and NF-κB requirements for optimal 
expression, but the strength of TLR4 signal needed to efficiently activate these mediators 
is unknown.  We determined the log(EC50) values for the activation of p38, c-Jun N-
terminal kinase (JNK), extracellular signal-regulated kinase 1/2 (ERK1/2), and IκBα by 
treating BMDC with a series of doses of sLipid A and quantifying relative protein 
abundance by Western blotting (Fig. 15A).  Significantly less sLipid A was needed to 
induce half-maximal IκBα degradation, as an indicator of NF-κB activation, and p38 
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activating phosphorylation [low log(EC50) values] compared to JNK and ERK1/2 
activating phosphorylation [high log(EC50) values] (Fig. 15B).  We were not surprised 
that NF-κB activation required very little agonist given its prominence as a readily 
triggered component of proinflammatory gene regulation, but the low potency with which 
the MAPKs JNK and ERK1/2 were activated was striking.  Thus, although MAPKs are 
influenced by both TRIF and MyD88 pathways, there are considerable differences in the 
ease with which they are activated. 
 
The high log(EC50) values of sLipid A for MyD88- and TRIF-co-dependent events 
correlate with a dependence on JNK 
We and others published previously that MAPKs differ in their involvement in 
transcription factor activation and gene expression downstream of TLR4 (78, 120-124).  
Although substantial overlap and redundancy in MAPK requirements for gene expression 
exist, specific TLR4-induced genes may have a greater requirement for certain MAPKs.  
It is unclear whether specific MAPKs preferentially control the expression of TRIF-
dependent versus co-dependent genes.  We hypothesized that the high log(EC50) values 
of agonists for the expression of co-dependent genes may be, in part, a result of their 
strong dependence on JNK, which is also associated with high log(EC50) values.  
Conversely, the low log(EC50) values of agonists for TRIF-dependent genes may be 
because their expression depends on p38 activity, which is characterized by a low 
log(EC50) value. 
To test this hypothesis, BMDC were pretreated with specific chemical inhibitors 
of JNK and p38 before measuring the effects of a range of concentrations of sLipid A on 
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TRIF- and co-dependent gene expression.  The efficacy (maximum amount) of MyD88-
dependent IL-6 protein production was reduced by JNK inhibition but not by p38 
inhibition (Fig. 16A), but neither inhibitor significantly changed the potency of sLipid A 
in stimulating IL-6 production (Fig. 16B).  The efficacy of the TRIF-dependent 
production of IP-10 protein was unchanged by JNK and p38 inhibitors (Fig. 16A).  Both 
inhibitors slightly reduced IP-10 production at doses of sLipid A below 1 nM (Fig. 16A).  
The JNK inhibitor caused a statistically significant increase in the log(EC50) value of 
sLipid A for IP-10 production, whereas the p38 inhibitor caused an increase in the 
log(EC50) for IP-10 that approached statistical significance (Fig. 16B).  Neither inhibitor 
increased the log(EC50) for IP-10 to match that for IL-6 production.  These data suggest 
that a varying dependence on specific MAPKs is unlikely to be the cause of the 
differences in log(EC50) values between co-dependent and TRIF-dependent events. 
Because the efficacy of sLipid A for the production of co-dependent IL-6, but not 
TRIF-dependent IP-10, was decreased by JNK inhibition, we explored the role of JNK 
signaling in expression of other TRIF-dependent or co-dependent genes.  JNK inhibition 
reduced the sLipid A-stimulated increases in MyD88-dependent Il6 and Cd80 mRNA at 4 
hours, but had no effect on TRIF-dependent Ip10 mRNA abundance (Fig. 16C).  JNK 
inhibition did significantly reduce the TRIF-dependent increase in Cd86 mRNA 
abundance at 4 hours, but less effectively than it inhibited increased Cd80 mRNA 
abundance (Fig. 16C).  Unexpectedly, inhibition of p38 had no significant effect on the 
expression of any genes (Fig. 16C), despite confirmation that SB202190 had been 
effectively delivered (Fig. 17).  Therefore, the expression of MyD88- and TRIF-co-
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dependent genes, such as Il6 and Cd80, correlates with a dependence on the JNK 
signaling pathway for full induction. 
 
The high log(EC50) value of sLipid A for Ifnb mRNA expression correlates with a 
dependence on JNK 
IFN-β production in response to TLR4 stimulation absolutely requires TRIF 
signaling and is downstream of the activation of IRF3 (48, 55, 125).  In addition, optimal 
IFN-β production requires intact MyD88 signaling (118), because the activity of the Ifnb 
promoter requires the activation of MyD88-associated transcription factors such as AP-1, 
which is activated downstream of JNK and NF-κB (126, 127).  Because JNK-dependence 
was correlated with co-dependent genes characterized by logEC50s, we wondered 
whether the log(EC50) value for the induction of Ifnb expression was also high.  We 
measured Ifnb mRNA abundance in BMDCs activated with a dose series of sLipid A and 
calculated the log(EC50) values at 1 hour, the time at which Ifnb mRNA was maximally 
expressed.  The log(EC50) value of sLipid A for Ifnb expression was substantially higher 
than that for TRIF-dependent Ip10 and was as high as that for co-dependent Il6 (Fig. 
18A).  To confirm that sLipid A-induced Ifnb expression was JNK-dependent, we 
pretreated BMDCs with JNK inhibitor and measured Ifnb mRNA abundance over time.  
As expected from previous reports (128, 129), Ifnb mRNA expression was markedly 
decreased in the absence of JNK signaling (Fig. 18B).  In contrast, p38 inhibition had 
relatively little influence on Ifnb expression, only slightly decreasing it at 1 hour (Fig. 
18B).  These data demonstrate that the TLR4-dependent expression of Ifnb is 




Autocrine and paracrine signaling by type I interferon determines the low log(EC50) 
values of sLipid A for TRIF-dependent responses 
Although we observed a correlation between JNK-dependence and MyD88- and 
TRIF-co-dependence, differential MAPK-dependence could not completely explain 
either the high log(EC50) values of TLR4 agonists for the expression of co-dependent 
genes or the low log(EC50) values for the expression of TRIF-dependent genes (Fig. 16).  
Alternatively, the lower log(EC50) values of agonists for TRIF-dependent events could 
be caused by crosstalk or synergy between TLR4 and other receptors.  In addition to 
inputs directly from TLR4, signaling through the IFN-α/β receptor (IFNAR) by secreted 
type I IFN enhances the expression of TRIF-dependent genes through the activation of 
the IFN-stimulated gene factor 3 (ISGF3) complex, which binds to and activates 
interferon stimulated response elements (ISREs) in gene promoters (130, 131). 
 We found that sLipid A induced robust Ifnb expression in BMDCs (Fig. 18).  
Therefore, we hypothesized that the relatively low log(EC50) values of sLipid A for 
TRIF-dependent gene expression were caused by enhancement of TRIF-dependent 
responses through secondary IFNAR signaling.  To determine the extent to which IFN-β 
alone could induce expression of TLR4-regulated genes, we exposed BMDCs to 
recombinant IFN-β or sLipid A and measured increases in steady-state TRIF-dependent 
Ip10 and Cd86 mRNA abundance, and compared them to changes in co-dependent Il6 
and Cd80 mRNA abundance.  As expected, the abundances of TRIF-dependent Cd86 and 
Ip10 mRNAs were increased by IFN-β treatment (Fig 19A).  In fact, the increases in 
steady-state mRNA abundance by IFN-β were comparable to those with sLipid A 
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stimulation, indicating that IFN-β is sufficient to induce the expression of Cd86 and Ip10 
(Fig. 19A).  In contrast, IFN-β stimulation caused no measurable increases in Cd80 
mRNA abundance and relatively small increases in Il6 mRNA abundance when 
compared to sLipid A stimulation (Fig. 19B).  Although both Cd80 and Il6 are type I 
IFN-responsive genes in certain contexts (130, 132-134), IFN-β was insufficient to 
induce their expression in BMDCs. 
 To determine whether autocrine and paracrine signaling by IFN-β was responsible 
for the low log(EC50) values of sLipid A for the expression of Ip10 and Cd86, we 
blocked IFNAR signaling by pre-treating BMDCs with the IFNAR1 antagonistic 
antibody MAR1-5A3, or isotype control, and measured the log(EC50) values of sLipid 
A.  We demonstrated that MAR1-5A3 was effective at blocking STAT1 phosphorylation 
downstream of IFNAR in response to sLipid A-induced type I IFN production at a 
concentration of 10 ug/ml (Fig. 20).  The efficacy, or maximal responses, of both TRIF-
dependent Ip10 and co-dependent Il6 mRNA expression were decreased in MAR1-5A3 
treated cells (Fig. 21A), consistent with both of these genes being type I IFN-inducible 
(Fig. 19A and B).  Despite dampening of global Il6 and Ip10 expression, the log(EC50) 
value of sLipid A for Ip10 was significantly increased, whereas the log(EC50) value for 
Il6 was unchanged (Fig. 21A).  Similarly, increases in Cd80 and Cd86 mRNA abundance 
were dampened by the addition of MAR1-5A3, but only the log(EC50) value of sLipid A 
for TRIF-dependent Cd86 was significantly increased (Fig. 21B).  Furthermore, the 
log(EC50) values of sLipid A for both TRIF-dependent Ip10 and Cd86 mRNA 
expression were increased to values similar to those for co-dependent Il6 and Cd80 
mRNA, suggesting that secondary signaling by IFNβ through IFNAR enhances the 
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potency of TLR4 agonists like sLipid A for TRIF-dependent gene expression (Fig. 21A 
and B).  We also tested whether secondary type I IFN signaling was responsible for the 
low log(EC50) values of sLipid A for TRIF-dependent protein production downstream of 
mRNA.  MAR1-5A3 treatment increased the log(EC50) values for IP-10 production, but 
not for IL-6 production, when compared to those in stimulated control cells (Fig. 21C).  
Together, these results show that autocrine and paracrine signaling via IFNAR is a 




 We and others have proposed that TLR4 adapter modulation is a function of an 
agonist’s structural characteristics.  Zughaier et al. (111) reported that LPSs from E. coli 
and Vibrio cholerae were MyD88-biased while LPSs from Salmonella species were 
TRIF-biased over a range of doses when compared to a Neisseria meningitidis 
lipooligosaccharide reference.  We later proposed that MPLA functions as a TRIF-biased 
agonist of mouse TLR4, relative to the LPS from which it is derived, in an effort to 
understand how MPLA maintains immunostimulatory activity in spite of losing 
approximately 99.9% of its inflammatory activity (77).  Bowen et al. (110) also reported 
TRIF-bias in demonstrating that the lipid A mimetic CRX-547 was significantly less 
efficacious than a stereoisomeric compound, CRX-527, in eliciting NF-κB activation and 
MyD88- and TRIF-co-dependent TNFα production, but was comparable in inducing 
TRIF-dependent IP-10 and RANTES. 
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Despite this evidence for TLR4 TRIF-bias, other data called its existence into 
question.  Earlier dose response experiments with mouse peritoneal macrophages 
demonstrated that MPL adjuvant was much less potent than LPS in activating both TRIF-
dependent IP-10 and co-dependent TNF-α and IL-1β (73).  More recently, Gaekwad et al. 
(113) tested preparations of a variety of lipid A structures proposed to modulate TLR 
adapter signaling.  Using mouse macrophage cell lines, they found no evidence for 
adapter modulation; instead cytokine and transcript potency data conformed to an 
additive model in which changes in agonist structure affect the potency for all genes 
equally regardless of their adapter association.  In addition, TLR4 mutagenesis studies 
were inconsistent with a clear structural basis for TRIF-biased signaling by 
monophosphorylated agonists (135). 
Our results support the conclusion that sMLA is not a TRIF-biased agonist of 
TLR4 relative to sLipid A because sMLA was approximately 10% as potent as sLipid A 
for both the TRIF- and MyD88- and TRIF-co-dependent genes we tested (Fig. 11).  
However, by comparing log(EC50) values, we found that TRIF-dependent genes are 
activated with significantly less TLR4 agonist than are MyD88- and TRIF-co-dependent 
genes (Fig. 12 and Fig. 13).  This characteristic seemed to be independent of TLR4 
agonist structure and potency because sMLA and Lipid IVa, two weaker agonists that 
differ in phosphorylation status and acyl chain number, also induced TRIF-dependent 
genes more effectively.  As we have only tested three different agonists, we have not 
definitively ruled out the possibility that other agonists may be incapable of this process. 
We demonstrated that the log(EC50) value of sLipid A for the increase in 
abundance of mRNA of the TRIF-dependent T cell costimulatory molecule Cd86 was 
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also low compared to the log(EC50)s for co-dependent genes such as Il6, Cox2 (Fig. 12), 
and Cd80 (Fig. 13), supporting the idea that enhancement of T cell priming can proceed 
without high amounts of MyD88-associated proinflammatory cytokine production, as 
was seen in our first in vivo adjuvant tests with MPLA (77).  Because all TRIF-dependent 
outcomes were characterized by low log(EC50) values compared to MyD88- and TRIF-
co-dependent outcomes, we propose that TLR4 itself, not sMLA, can be considered to be 
TRIF-biased. 
We were able to discard several possible mechanisms for TLR4 TRIF-bias.  TRIF 
adaptor engagement was not likely induced at lower doses of TLR4 agonist than was 
MyD88 adaptor engagement because the log(EC50) values of sLipid A for TRIF-
dependent activating phosphorylation of IRF3 and for MyD88-dependent 
polyubiquitination of IRAK1 were not significantly different (Fig. 14).  In fact, two 
paired experiments seemed to indicate that TRIF signaling was initially more difficult to 
induce, which is not surprising given that MyD88 signaling occurs at the plasma 
membrane whereas TRIF signaling requires comparatively more complex CD14-
dependent endocytosis of TLR4 (47).  In addition, differential requirements for JNK are 
unlikely to explain TRIF-biased signaling because inhibition of JNK had little effect on 
the log(EC50) values of sLipid A in its stimulation of the expression of either TRIF-
dependent or co-dependent genes (Fig. 16). 
Many TRIF-dependent genes are also type I IFN-inducible and their activation in 
response to TLR4 stimulation decreases dramatically in the absence of IFN-β within a 3 
hour timeframe (130) indicating that autocrine and paracrine signaling by type I IFN may 
be involved in TLR4 TRIF-bias.  When we blocked type I IFN signaling, we found that 
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the log(EC50) values for the expression of TRIF-dependent genes increased to values 
similar to those of co-dependent genes, suggesting that the TRIF-biased nature of TLR4 
depends  on IFNAR (Fig. 21).  In contrast, blocking IFNAR did not change the 
log(EC50) values for the MyD88- and TRIF-co-dependent production of IL-6 and 
increase in Cd80 mRNA abundance; however, IFNAR inhibition led to a decrease in their 
maximum abundance, suggesting that IFNAR signaling enhances the expression of their 
respective genes.  TRIF-dependent, IFN-β-sufficient genes appear to be characterized by 
low log(EC50) values because they are regulated primarily by transcription factors that 
are activated by autocrine and paracrine IFNAR signaling stimulated by type I IFN 
released in response to TLR4 activation (130). 
Though many consider IFN-β to be the canonical TRIF-dependent gene, it may be 
characterized more accurately as MyD88- and TRIF-co-dependent because its production 
is reduced in the absence of MyD88 signaling (118).  Like other co-dependent genes, the 
log(EC50) values of sLipid A for Ifnb mRNA expression is high compared to those of 
TRIF-dependent genes.  Moreover, its expression is JNK-dependent, in line with co-
dependent genes (Fig. 18).  Compared to other genes which absolutely require TRIF 
signaling to be expressed, the promoter complexity of Ifnb is high, requiring inputs from 
AP1, NF-κB, and IRF3 (126, 127).  In contrast, the promoter of TRIF-dependent IFIT-1 
has been shown to only contain ISREs (136).  Therefore, differences in promoter 
complexity likely contribute to the relatively high log(EC50) of agonists for Ifnb 
expression. 
It is unclear how TRIF-dependent responses characterized by low log(EC50) 
values could be caused by IFN-β, a gene product characterized by high log(EC50) values.  
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One possibility is that IFN-β is a potent inducer of the expression of TRIF-dependent 
genes.  Additionally, locally high concentrations of secreted IFN-β may be present 
around the responding cell, which may enhance the effective potency of this cytokine.  
We have also not ruled out contributions from IFN-α, which may be produced in 
response to TLR4 stimulation in certain contexts (137).  From a teleological perspective, 
the high log(EC50) value for IFN-β production may be beneficial to the host during 
infection, because type I IFNs can contribute to endotoxic shock and the production of 
proinflammatory IL-1β through the activation of caspase-11 (138, 139).  These 
observations suggest that IFN-β may have biphasic functionality, supporting adaptive 
immune priming at low concentrations and becoming more proinflammatory at high 
concentrations. 
In conclusion, our results provide a new understanding of TLR4 TRIF-bias.  In 
our culture system, monophosphorylation of lipid A did not cause TRIF-bias; rather, 
TLR4 itself signaled in a TRIF-biased manner in which TRIF-dependent, IFN-β-
sufficient genes associated with T cell priming were induced with less agonist than co-
dependent genes associated with proinflammatory outcomes.  The extent to which TRIF-
bias can occur will likely depend upon a cell type’s ability to respond to type I IFN 
within the system and to the characteristics of type I IFN-inducible gene regulation 
within that cell.  These results are relevant to ongoing translational efforts because sMLA 
is the active component of GLA (glucopyranosyl lipid adjuvant) formulations that are 
being tested clinically (140).  Future studies are needed to determine whether cell types 
other than mouse BMDC, including human cells, are capable of agonist-independent 
TRIF-bias.  We have also not ruled out the ability of other species or cell types to 
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undergo true TRIF-biased agonism based on agonist structural features, which may 






Fig. 11. sMLA is not a TRIF-biased TLR4 agonist. (A) BMDCs from C57BL/6 mice 
were treated with the indicated concentrations of sMLA or sLipid A. After 4 hours, 
increases in the steady-state abundances of the indicated mRNAs in agonist-treated cells 
compared to those in vehicle-treated cells were determined by qPCR analysis. After 18 
hours, the amounts of the indicated proteins that were secreted into the culture media 
were determined by ELISA. Fold increases in mRNA abundance were converted to 
percentages of the maximal response measured in each experiment. Data are means ± 
SEM of three independent experiments. Insets show log(EC50) values (with SE values in 
parentheses) derived from the goodness of the fit of the nonlinear regression calculation. 
(B) The sLipid A logEC50 values were subtracted from the sMLA logEC50 values for 
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each analyte measured in (A) within each independent experiment, and then graphed.  
The logEC50 difference represents the potency difference between sMLA and sLipid A. 
Solid grey bars represent MyD88- and TRIF-co-dependent gene products and white bars 
represent TRIF-dependent gene products. The striped bar represents the average logEC50 
difference between sMLA and sLipid A calculated for all analytes within each 
independent experiment.  Data are mean log(EC50) differences ± SEM from three 
independent experiments. Differences between the means were not statistically 
significant when analyzed by one-way ANOVA (P > 0.05). (C) The amounts of IL-6 and 
IP-10 proteins secreted by BMDCs in response to the indicated concentrations of sLipid 
A and sMLA from the experiments shown in (A) are plotted to show the appearance of 





        
 
Fig. 12. The expression of TRIF-dependent genes is activated with lower 
concentrations of TLR4 agonists than are required for the expression of MyD88- 
and TRIF-co-dependent genes. (A) Log(EC50) values of the sLipid A– and sMLA-
stimulated changes in the abundances of the indicated proteins and mRNAs from the 
experiments shown in Fig. 1A. Individual log(EC50) values and mean values from three 
independent experiments (vertical bars) are shown. (B) BMDCs from C57BL/6 mice 
were activated with half-log dilutions of Lipid IVa or sLipid A for 18 hours, after which 
IP-10 and IL-6 concentrations in culture media were measured by ELISA. Left: 
Individual log(EC50) values from three independent experiments were compared. 
Nonlinear regression analysis of the means ± SEM of those experiments is shown for IL-
6 (middle) and IP-10 (right). Insets show log(EC50) values with SE values given in 
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parentheses. Statistical differences were analyzed for the data in (A) and (B) by an 
unpaired, two-tailed t test or by one-way ANOVA with Tukey’s post-test. *P < 0.05; **P 







Fig. 13. The TRIF-dependent expression of Cd86 is activated with lower TLR4 
agonist concentrations than are required for the MyD88- and TRIF-co-dependent 
expression of Cd80. (A) BMDCs from wild-type (WT), MyD88-/-, or TRIFLps2/Lps2 mice 
were treated with vehicle control (VC) or were stimulated with the indicated 
concentrations of sLipid A for 4 hours. The steady-state abundances of Cd80 and Cd86 
mRNAs were then analyzed by qPCR. Data are the mean fold-increases in mRNA 
abundance in sLipid A–stimulated cells compared to those in vehicle-treated cells and are 
combined from two independent experiments. (B) Log(EC50) values were determined for 
the sLipid A–stimulated increases in the abundances of Cd80 and Cd86 mRNAs after 4 
hours by nonlinear regression analysis. Data are means ± SEM from three independent 
experiments. Right: Log(EC50) values from individual experiments. Statistical 







Fig. 14. Low log(EC50) values for TRIF-dependent genes are not explained by 
biased adaptor use. (A) BMDCs from WT mice were treated with vehicle (VC) or were 
stimulated with a half-log dilution series of sLipid A for 1 hour. Samples were then 
analyzed by Western blotting with antibodies specific for the indicated proteins. The 
abundances of IRAK1 and pIRF3 (Ser396) were quantified by densitometric analysis and 
normalized to those of β-actin and total IRF3, respectively. Representative blots are 
shown. Normalized values from densitometric analysis were converted to percentage 
maximal responses for each experiment. Data in graphs are means ± SEM from four 
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independent experiments. (B) Individual log(EC50) values (squares and triangles indicate 
matched experiments) and means from the experiments shown in (A) were plotted and 







Fig. 15. The logEC50s of sLipid A for MAPKs and NF-κB are distinct. (A) BMDCs 
from WT mice were treated with vehicle as a control (VC) or were stimulated with a half-
log dilution series of sLipid A for 15 min. Samples were then subjected to Western 
blotting analysis to determine the relative extents of phosphorylation of JNK 
(Thr183/Tyr185), p38 (Thr180/Tyr182), and ERK1/2 (Thr202/Tyr204), as well as of the 
degradation of IκBα. Representative Western blots are shown. Densitometric analysis 
was performed to determine the relative abundances of the indicated phosphorylated 
proteins normalized to the abundances of their respective total proteins, whereas IκBα 
abundance was normalized to that of β-actin. Normalized values were converted to 
percentage maximal responses for each experiment. Data are means ± SEM from the 
nonlinear regression analysis of at least four independent experiments. (B) Log(EC50) 
values from the independent experiments shown in (A). Statistical differences were 





Fig. 16. MyD88- and TRIF-co-dependent genes with high log(EC50) values have a 
greater dependence on JNK for their expression than do TRIF-dependent genes. (A) 
BMDCs from WT mice were pretreated with the JNK inhibitor SP600125, the p38 
inhibitor SB202190, or DMSO (vehicle) for 30 min before being stimulated with a half-
log dilution series of sLipid A for 18 hours. The concentrations of secreted IL-6 and IP-
10 proteins in the culture media were then measured by ELISA. Data are means ± SEM 
from the nonlinear regression analysis of at least three independent experiments. (B) 
Log(EC50) values were calculated from the dose-response curves of the independent 
experiments shown in (A) and then were compared by two-way ANOVA with Sidak’s 
post-test. *P < 0.05; ns, not statistically significant. (C) BMDCs from WT mice were 
pretreated with DMSO or the indicated inhibitors for 30 min before being treated with 
vehicle (VC) or sLipid A (100 ng/ml) for the indicated times. Increases in the steady-state 
abundances of the indicated mRNAs in sLipid A–treated cells compared to those in 
vehicle-treated cells were determined by qPCR analysis. Data are means ± SEM from 
four independent experiments. Statistical differences between agonist-treated samples 
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and DMSO-treated samples were analyzed with repeated measures two-way ANOVA 








Fig. 17. SB202190 and SP600125 inhibit p38 MAPK and JNK signaling, 
respectively. (A and B) BMDCs from wild-type mice were pre-incubated with DMSO 
(vehicle control) or increasing concentrations of (A) SB202190 (a p38 inhibitor) or (B) 
SP600125 (a JNK inhibitor) for 30 min. Cells were then treated with DMSO (vehicle 
control) or were stimulated with sLipid A (100 ng/ml) for 15 min. Samples were then 
subjected to Western blotting analysis with antibodies specific for the indicated proteins. 






Fig. 18. The high log(EC50) values for the expression of Ifnb correlate with a 
dependence on JNK signaling. (A) BMDCs from WT mice were stimulated with a half-
log dose series of sLipid A for 1 hour. The steady-state abundance of Ifnb mRNA in each 
of the samples was determined by qPCR analysis, and fold-increases in mRNA 
abundance in agonist-treated cells compared to that in vehicle-treated cells were 
calculated and then converted to percentage maximal responses for each experiment. 
Top: Data are means ± SEM of three independent experiments that were subjected to 
nonlinear regression analysis. Bottom: One hour Ifnb logEC50s are compared to those of 
Il6 and Ip10 (reproduced from Fig. 2A), both measured at 4 hours (bottom). (B) BMDCs 
from WT mice were pretreated with the indicated inhibitors or DMSO for 30 min before 
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being treated with vehicle (VC) for 1 hour or with sLipid A (100 ng/ml) for the indicated 
times. The abundance of Ifnb mRNA in each sample was determined by qPCR analysis. 
Data are means ± SEM in the fold increase in Ifnb mRNA in agonist-treated cells 
compared to that in vehicle-treated cells and are from three independent experiments. 
Statistical differences between agonist-treated and DMSO-treated samples were 
determined by repeated measures two-way ANOVA with Dunnett’s post-test. *P < 0.05; 







Fig. 19. IFN-β is sufficient to induce the maximal expression of genes with low 
log(EC50) values. (A and B) BMDCs from WT mice were activated with either IFN-β 
(1000 U/ml) or sLipid A (100 ng/ml) for the indicated times. Samples were then analyzed 
by qPCR, and the relative fold-increases in the abundances of the mRNAs of (A) TRIF-
dependent and (B) MyD88- and TRIF-co-dependent genes in stimulated cells compared 
to those in DMSO-treated cells were determined. Data are means ± SEM from at least 
three independent experiments. Statistical differences between sLipid A- and IFN-β-
stimulated mRNA abundances at each time point were determined by two-way ANOVA 
with Sidak’s post-test. *P < 0.05; **P < 0.01, ***P < 0.001, ****P < 0.0001; NS, not 







Fig. 20.  MAR-5A3 effectively blocks IFNAR signaling.  WT BMDC were 
preincubated with the indicated concentrations of MAR1-5A3 or media alone for 1 hour.  
The cells were then activated with 100 ng/ml sLipid A for 1 hour.  Intracellular staining 
for pSTAT1 was performed.  Data were collected on a FACScalibur.  The percentage of 





Fig. 21. Autocrine and paracrine signaling by IFN-β contributes to the low 
log(EC50) values of TRIF-dependent genes. (A to C) BMDCs from WT mice were 
pre-treated with MAR1-5A3 (an anti-IFNAR1 antibody) or isotype control antibody for 2 
hours before being stimulated with a half-log dose series of sLipid A for 4 or 18 hours. 
(A and B) After 4 hours, samples were analyzed by qPCR to measure the steady-state 
abundances of the indicated mRNAs in stimulated cells relative to those of vehicle-
treated cells. (C) After 18 hours, the concentrations of the indicated proteins in the culture 
media were determined by ELISA. Data are means ± SEM from the nonlinear regression 
analysis of at least three independent experiments. Right: The log(EC50) values derived 
from each experiment were averaged and are compared in bar graphs. Statistical 
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differences between the log(EC50) values of isotype -treated and MAR1-5A3–treated 
cells were determined by repeated measures two-way ANOVA with Sidak’s post-test. 






CD14 DOES NOT PLAY A SPECIAL ROLE IN TLR4 SIGNALING IN RESPONSE 
TO MONOPHOSPHORYL LIPID A 
 Following our proposal that MPLA induced a TRIF-biased response by TLR4, 
our search for potential mechanisms led us to consider the coreceptor CD14.  Although 
CD14 is well known to enhance the expression of MyD88-associated genes in response 
to TLR4 agonists, its primary role in driving endocytosis of TLR4-MD2 signaling 
complexes to initiate TRIF signaling has only recently come to light (47).  We reasoned 
that a TRIF-biased agonist may utilize CD14 in a different manner than a MyD88- and 
TRIF-balanced agonist. 
Although CD14 promotes endocytosis of TLR4 through a Syk- and PLCγ2-
dependent pathway, the exact mechanism by which it activates this pathway is unknown.  
For example, it is unknown whether CD14 must bind its ligand directly, or if its mere 
presence on the cell surface promotes internalization.  It is likely that in the process of 
transferring ligands to TLR4-MD2, the dimeric CD14 molecule promotes 
heterotetramerization of TLR4-MD2 by physically bringing together the two complexes.  
In fact, the distance between the ligand-binding domains of CD14 corresponds closely to 
the distance between adjacent MD2 molecules in the heterotetramer (141).  Perhaps this 
transient interaction with TLR4-MD2 promotes the endocytic pathway. 
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The ligand-binding pocket of CD14 is large and hydrophobic with charged 
residues around its rim (85).  These charged residues are thought to interact with the 
hydrophilic headgroup of lipid A.  Because MPLA contains one less phosphate, it is 
conceivable that its interaction with CD14 may be different than that of lipid A, but we 
found little evidence to suggest that MPLA utilizes CD14 differently than lipid A.  Our 
data suggest that CD14 ablation decreases the potency of lipid A and MPLA to the same 
extent.  This is not surprising given the ability of CD14 to bind molecules with 
significantly different structures. 
Our results also confirm the importance of CD14 in the initiation of the TRIF 
pathway because the efficacy of lipid A was reduced by 50% for induction of TRIF-
dependent Ifit1 expression.  The efficacy of lipid A for MyD88-associated events, on the 
other hand, was not decreased.  Interestingly, Tanimura et al. (93) have shown that CD86 
upregulation on BMDCs in response to lipid A and MPLA is unaffected by CD14 
ablation, despite the fact that this process is TRIF-dependent.  This group suggests that in 
the absence of CD14, some TRIF-dependent signaling may originate from the cell 
membrane, which is sufficient to induce certain TRIF-dependent responses.  Therefore, 
TRIF-dependence and CD14-dependence should not be considered one in the same.  
Perhaps alternative methods exist to initiate TRIF signaling independent of endocytosis 
of TLR4-MD2 heterotetramers. 
 
IMPLICATIONS FOR VACCINE ADJUVANTS 
 Observation of “biased agonism” is not unique to TLR4.  This phenomenon has 
long been recognized to occur with members of the G protein-coupled receptor (GPCR) 
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family, the largest class of receptors in the human genome (142).  GPCR signaling is 
mediated by two groups of adaptor proteins, the heterotrimeric G proteins and the 
arrestins, the most common of which are the β-arrestins (143).  Similar to the TLR4 
adaptor proteins MyD88 and TRIF, G proteins and β-arrestins mediate different 
downstream signaling events.  Exchange of GDP for GTP by the Gα subunit induces 
signaling through second messenger systems such as cyclic AMP (143).  The β-arrestins 
are involved in GPCR desensitization and internalization, MAPK activation, and can also 
serve as cofactors during transcription (143).  Initially, it was thought that GPCR ligands 
induced balanced signaling through G proteins and β-arrestins, but there are now many 
studies confirming that certain ligands can induce biased signaling through either 
pathway, which may be caused by the existence of multiple active receptor 
conformations (144).  For example, SII angiotensin, a synthetically modified agonist of 
the angiotensin II type IA receptor, is unable to activate Gαq signaling, but retains 
activation of β-arrestin 2 which leads to ERK activity (145, 146). 
Similar to modification of LPS to reduce its toxicity while maintaining 
adjuvanticity, GPCR agonists are being developed to selectively target therapeutically 
beneficial signaling pathways.  Stimulation of the μ-opioid receptor by morphine induces 
clinically beneficial analgesic affects but is also associated with detrimental side-effects 
such as constipation and respiratory depression (147).  These side-effects have been 
linked to β-arrestin 2 signaling (147).  A morphine derivative called TRV130 has recently 
been shown to be better tolerated by patients because it induces signaling biased toward 
the G protein pathway (148, 149).  Therefore, a strong precedent has been set for 
harnessing biased receptor signaling to target clinically useful outcomes more effectively. 
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 Unexpectedly, this dissertation provides evidence that neither MPLA nor sMLA 
are bona fide TRIF-biased agonists.  In fact, they were less potent than their 
corresponding diphosphorylated agonist (lipid A or sLipid A) by the same magnitude for 
the expression of both TRIF-dependent and MyD88- and TRIF-co-dependent genes 
(Chapters III and IV).  Instead, we provide evidence to suggest that TLR4 itself can 
behave as a TRIF-biased receptor.  When using synthetic agonists, the amount of agonist 
required to induce half-maximal TRIF-dependent gene expression was significantly less 
than the amount of agonist needed to induce that of MyD88- and TRIF-co-dependent 
gene expression.  TRIF-bias by TLR4 was not at the level of early adaptor engagement 
because there was no significant difference between the log(EC50) values of sLipid A for 
MyD88-dependent IRAK1 disappearance and TRIF-dependent IRF3 phosphorylation.  
The log(EC50) values of sLipid A for the downstream activation of MAPKs and NF-κB 
began to diverge, even though these events are MyD88- and TRIF-co-dependent.  The 
strikingly consistent difference between the log(EC50) values for TRIF- and co-
dependent events occurred at the level of gene expression and protein secretion.  
According to our model, autocrine and paracrine signaling by type I IFN produced in 
response to TLR4 activation contributes to the relative ease with which TRIF-dependent 
genes are activated (Fig. 22). 
 We have yet to fully explain the paradox whereby the expression of a gene 
characterized by a high log(EC50) value, Ifnb, can promote the low log(EC50) values of 
agonists for TRIF-dependent genes.  In this work, we have only characterized the 
log(EC50) value for increases in steady-state Ifnb mRNA abundance.  The log(EC50) 
value for the secretion of IFN-β protein may in fact be lower which would support our 
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hypothesis that an autocrine and paracrine signaling loop through IFNAR promotes 
TLR4 TRIF-bias.  These tests are underway.  As discussed in Chapter IV, the potency of 
IFN-β may also be sufficient to promote TRIF-bias, even when the IFN-β concentration 
is relatively low. 
 Other non-mutually exclusive mechanisms may also be involved in TLR4 TRIF-
bias.  One hypothesis is that gene promoter complexity may promote a TLR4 TRIF-
biased gene expression profile.  In general, genes which require MyD88-dependent 
signaling for full activation (i.e. co-dependent genes) may have more complex promoters 
with multiple NF-κB and AP1 binding sites.  TRIF-sufficient genes likely have less 
complex promoters which require fewer cofactor inputs for sufficient expression.  For 
example, TRIF-dependent Ifit1 has only two ISREs in its promoter (136) and Ip10 
expression requires either two NF-κB binding sites or one NF-κB binding site and one 
ISRE (150).  Therefore, it is plausible that TRIF-dependent genes may simply be more 
easily activated because less TLR4 agonist is needed to induce the transcriptional inputs 
required to express these genes. 
 It should be noted that neither MPLA nor lipid A seemed to conform to our model 
of TLR4 TRIF-bias in the experiments presented in Figure 4.  In these experiments, the 
log(EC50) values for MPLA and lipid A for Ifit1 mRNA expression were not lower than 
those for co-dependent IL-6 and Cox2 mRNA.  A direct comparison of the log(EC50) 
values of sLipid A and lipid A, under the same conditions, for TRIF-dependent and co-
dependent gene expression will need to be completed before we can confirm that TLR4 
TRIF-bias is not exhibited with these biological compounds. 
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 A major limitation to the studies presented herein is that they were all assessed in 
vitro.  Therefore, they do not take into account the complex interplay between different 
cell types that occurs during vaccination or infection.  We chose to perform this work 
using BMDC because DC are expected to be the most important cells in the context of 
immunization.  But other cell types, such as monocytes and macrophages certainly 
respond during immunization as well.  Whether or not these cell types exhibit TLR4 
TRIF-bias must be determined in the future. 
Although we have not directly tested this hypothesis in vivo, work by Mata-Haro 
et al. (77) does suggest that TLR4 TRIF-bias may occur within a living host.  In this 
study, both serum cytokine and spleen cell mRNA measurements after immunization 
with LPS or MPLA demonstrated that the weak agonist MPLA was TRIF-biased relative 
to LPS.  This observation could very well be explained by inherent TRIF-bias by TLR4 
itself, especially since a higher dose of MPLA than LPS was used in these studies.  A 
definitive test of this hypothesis would be to perform immunizations with a series of 
dilutions of a potent agonist, like LPS or lipid A, and compare TRIF- and co-dependent 
outcomes.  Our hypothesis predicts that a dose of LPS or lipid A exists that mirrors the 
response induced by MPLA, both in T cell priming and cytokine production.  While our 
results clearly show that the potency of TLR4 agonists for TRIF-dependent events is 
higher than that of co-dependent events, they do not inform us of the actual levels of 
TLR4 signaling events needed to induce sufficient T cell priming.  By studying limiting 
doses of agonists in vivo, we can bypass issues of the physiological relevance of 
pharmacological potency and efficacy measured in vitro. 
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 Our findings have direct implications for the use of TLR4 agonists as vaccine 
adjuvants.  A paradigm has emerged in which TRIF-dependent gene activation is 
associated with events necessary for adaptive T cell priming and MyD88-associated gene 
activation is linked to proinflammatory cytokine release and toxicity.  Safe and 
efficacious vaccine adjuvants should induce maximal beneficial effects with the least 
amount of toxicity.  We speculate that TLR4’s TRIF-biased gene activation profile 
effectively widens the therapeutic window in which TLR4 agonists may be used as 
clinical adjuvants (Fig. 23).  In other words, there may be a broad range of doses at which 
a TLR4 agonist may be administered where adjuvanticity is retained and toxicity remains 
low.  Inherently less potent adjuvants like MPLA and sMLA may be better able to fit 
within this therapeutic window when administered in vivo.  At their effective doses, these 
agonists may also retain sufficient levels of MyD88-associated proinflammatory cytokine 
production which is likely important to promote long term immunity through effects on 
regulatory T cells (Tregs) and retention of memory T cells (151, 152). 
Our observation that type I IFN production was responsible for much of the TLR4 
TRIF-biased gene expression may also provide insight into the development of more 
effective adjuvants.  There is currently much interest in the combination of vaccine 
adjuvants to promote more robust immunity (153).  Specifically, combining TLR4 with 
TLR7, TLR8, or TLR9 agonists was shown to synergistically enhance production of IL-
12 and IL-23 in human and mouse DC, which promoted Th1 immunity (154).  TLR7 and 
TLR9 are expressed on plasmacytoid DC (pDC) and their activation induces production 
of large quantities of type I IFN (155), which induces many effects including APC 
maturation and migration, and B cell isotype switching (156).  We speculate that the 
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efficacy of combining TLR4-based adjuvants with those that target pDC may lie in the 
enhanced production of type I IFN.  In fact, a candidate clinical vaccine against a 
Mycobacterium tuberculosis antigen was recently shown to be more effective at inducing 
a Th1 response when adjuvanted with GLA (a formulation of sMLA) and CpG (a TLR9 
agonist) as opposed to GLA alone (157).  Adjuvant synergy between GLA and CpG was 
independent of TRIF signaling, but the adjuvant effects of GLA alone were TRIF-
dependent.  This result could be explained by rescue of TRIF-dependent, type I IFN-
inducible gene expression by the TLR9 signaling component.  Type I IFN signaling 
through IFNAR, either before or during TLR4 activation on conventional DC, may 
promote an even greater bias toward TRIF-dependent gene activation and further enhance 
adaptive immune priming and optimal T cell differentiation. 
 Preliminary studies in our lab using the human monocytic cell line THP1 and 
human peripheral blood mononuclear cells suggest that inherent TLR4 TRIF-bias is 
likely relevant to clinical medicine, but additional work needs to be performed to 
determine whether autocrine and paracrine signaling by type I IFN drives this response.  
Certain TLR4 agonist structures may also be TRIF-biased (i.e. ligand bias rather than 
receptor bias) in the human system as was demonstrated by Bowen et al. (110).  Current 
studies in our lab have shown that the biological mixture MPLA has a lower efficacy than 
lipid A for MyD88-associated gene expression in human cells.  In contrast, the efficacy 
of sMLA for these events is equivalent to that of sLipid A.  The lower efficacy of MPLA 
compared to sMLA may be explained by the presence of hypo-acylated congeners within 
the MPLA mixture that either act as antagonists or partial agonists of TLR4.  
Interestingly, studies performed by the Infectious Disease Research Institute (IDRI) 
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demonstrated that GLA was generally stronger than MPLA at inducing co-dependent and 
TRIF-dependent cytokines in human DC, including those implicated in adverse events 
such as TNFα and IL-6 (158).  Therefore, the fact that GLA is a homogeneous 
preparation of hexa-acylated molecules may be a barrier to its incorporation into clinical 
vaccines.  MPLA, on the other hand, may be a more tolerable vaccine adjuvant due to its 
heterogeneity which serves to tone down TLR4 activity. 
 
IMPLICATIONS FOR COEVOLUTION OF COMMENSAL BACTERIA AND 
INNATE IMMUNITY 
It is tempting to speculate on the selective pressures that would have promoted the 
evolution of bias toward the TRIF pathway of TLR4.  An answer may lie in the 
interaction between the host and its resident gut microbiota, which is essential for 
competent host immune system development, nutrition, and for maintenance of the 
mucosal barrier (159).  Trillions of bacteria colonize the host mucosal surfaces.  These 
bacterial colonies, although essential to host health, must be held in check by the host 
immune system.  An overly vigorous response to commensal bacteria may promote 
disease states such as colitis.  On the other hand, an inadequate immune response can 
promote infection by normally benign microbes.  The importance of gut microbiota 
homeostasis is demonstrated by the fact that disruption of commensal populations by 
antibiotic use promotes susceptibility to pathogenic Clostridium difficile infection (160). 
Intestinal CD103+ DC play an essential role in the maintenance of gut microbiota 
homeostasis (161).  These cells reside in the lamina propria and the gut-associated 
lymphoid tissue, and extend dendrites between intestinal epithelial cells to sample 
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commensal antigens within the lumen (161, 162).  Commensal bacteria themselves also 
relay signals to immune cells and lymphoid tissues through the release of PAMP-
containing membrane microvesicles that transverse the gut epithelium (163, 164).  To 
prevent an overly robust immune response to commensal bacteria, CD103+ DC promote 
the differentiation of commensal-specific induced T regulatory cells (Treg) through 
production of retinoic acid and TGF-β (161).  These Treg then promote commensal 
tolerance. 
Although tolerance to gut antigens is important, a mechanism must be in place to 
limit commensal loads and elicit immunity in the case of infection.  Intestinal DC support 
Th17 effector cell differentiation through production of IL-23 and IL-6 (161, 165).  Th17 
cells play an important role in controlling gut microbiota.  They promote the production 
of IgA (166), which limits commensal escape into the periphery (167), and have been 
implicated in lessening the severity of T cell-mediated colitis (168). 
 Interestingly, many commensal bacteria express weak TLR4 agonists 
characterized by hypo-acylation or monophosphorylation (169-171).  In addition, 
intestinal alkaline phosphatase (IAP) concentrated in the intestinal brush border and 
produced in response to bacterial colonization has been proposed to promote tolerance to 
commensal Gram-negatives by decreasing the potency of their LPS through the removal 
of the lipid A 1-phosphate group (172).  IAP-deficient zebrafish exhibited severe gut 
inflammation characterized by heightened infiltration of neutrophils (172).  We speculate 
that commensal bacteria may express weakened forms of LPS, produced either 
endogenously or by chemical modification by the host, to prevent strong TLR4 activity in 
intestinal DC that may promote Th17 mediated immunity over Treg mediated tolerance.  
91 
 
Weak activation of TLR4 on intestinal DC would be expected to induce a higher level of 
TRIF-dependent versus co-dependent gene activation in the context of our model of 
TRIF-bias.  Whether or not TRIF signaling plays a predominant role in maintenance of 
Tregs and tolerance is uncertain, but one study showed that TRIF signaling by gut DC in 
response to intestinal Candida albicans infection was required for Treg induction through 
the production of indoleamine dioxygenase (173). 
In cases where the T effector to Treg ratio should increase, such as infection by a 
pathogen, higher levels of TLR4 stimulation may occur through exposure of DC to higher 
bacterial loads or to more potent LPS chemotypes.  In this scenario, MyD88-associated 
genes would be more efficiently induced and promote conversion of tolerogenic DC to 
those which promote inflammation and immunity.  For example, stronger stimulation of 
gut DC through TLR4 may induce more robust production of co-dependent IL-6 which 
promotes Th17 differentiation (161, 174).  We speculate that commensal bacteria may 
have been selected to express low potency LPS structures in order to minimize clearance 
by the host immune system.  In addition, differential ease of activating TRIF- versus 
MyD88-associated gene expression by host APC may have coevolved with the 
microbiota to strike a balance between tolerance and immunity, which allows these 
beneficial bacteria to persist without damage to the gut, or other host-environment 





Fig. 22.  The proposed mechanism for TRIF-biased TLR4 signaling.  TLR4 
activation induces the expression of MyD88- and TRIF-co-dependent genes which 
require the activation of NF-κB and AP1 transcription factors.  TRIF dependent signaling 
activates IRF3, which, together with NF-κB and AP1, promotes type I IFN expression 
and low levels of type I IFN-inducible gene expression.  Type I IFN secreted by the cell 
activates ISGF3 through IFNAR signaling.  ISGF3 then promotes the expression of type I 
IFN-inducible genes.  The combined action of IRF3 and ISGF3, as well as other 
transcription factors, may increase the potency of TLR4 agonists for the induction of 
TRIF-dependent genes.  Though optimal co-dependent gene expression may require 





Fig. 23.  TLR4 TRIF-bias opens a therapeutic window for vaccine adjuvants.  The 
therapeutic window shaded in blue represents doses of a TLR4 agonist that induce TRIF-
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